Epidemiology and Risk factors of Distal Sensory Neuropathy in a Cohort of HIV Positive Individuals on First Line Combination Anti-Retroviral Therapy - A Prospective Observational Study. by Prabhakar, A T
 
 
 
 
 
EPIDEMIOLOGY AND RISK FACTORS 
 
OF DISTAL SENSORY NEUROPATHY IN A 
 
COHORT OF HIV POSITIVE INDIVIDUALS ON 
 
FIRST LINE COMBINATION ANTI-RETROVIRAL 
 
THERAPY – A PROSPECTIVE 
 
OBSERVATIONAL STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EPIDEMIOLOGY AND RISK FACTORS 
 
OF DISTAL SENSORY NEUROPATHY IN A 
 
COHORT OF HIV POSITIVE INDIVIDUALS ON 
 
FIRST LINE COMBINATION ANTI-RETROVIRAL 
 
THERAPY – A PROSPECTIVE 
 
OBSERVATIONAL STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment of Doctor of 
Medicine- Brach I – Neurology Degree Examination of the 
Tamil Nadu Dr.M.G.R Medical University, Chennai to be 
held in August 2013 
  
 
CERTIFICATION 
This is to certify that the dissertation entitled “Epidemiology and 
risk factors of Distal Sensory Neuropathy in a cohort of HIV 
Positive Individuals on first line combination anti-retroviral therapy 
– a prospective observational study” is the bonafide original work 
of Dr.A.T.Prabhakar towards the D.M Branch-1 Neurology  Degree 
Examination of the Tamil Nadu Dr. M.G.R Medical University, 
Chennai to be conducted in August 2013. 
 
 
 
 
 
 
 
 
 
  
 
 
                                                                Head of the unit:   Dr. Mathew Alexander,                                                      
Professor and Head 
Department of Neurology,   
 Christian Medical College,                                         
                                                                                                  Vellore – 632002                                                           
  
CERTIFICATION 
This is to certify that the dissertation entitled “Epidemiology and 
risk factors of Distal Sensory Neuropathy in a cohort of HIV 
Positive Individuals on first line combination anti-retroviral therapy 
– a prospective observational study” is the bonafide original work 
of Dr.A.T.Prabhakar towards the D.M Branch-1 Neurology  Degree 
Examination of the Tamil Nadu Dr. M.G.R Medical University, 
Chennai to be conducted in August  2013. 
 
 
 
 
 
 
 
 
 
  
 
            
 
                                                                            Guide:  Dr. Mathew Alexander,                                                      
Professor and Head 
Department of Neurology,   
 Christian Medical College,                                         
                                                                                                  Vellore – 632002                                                          
 ACKNOWLEDGEMENTS 
 
Above all I am grateful to God for his guidance in all circumstances. I would like to 
mention the following people with gratitude, for the help rendered towards the 
completion of this thesis: 
 
1. Dr.Mathew Alexander, Professor & Head of Department of Neurology 
CMC,Vellore for his expert supervision, guidance & constant encouragement. 
2. Dr.O.C.Abraham,Professor & Head of Department of Medicine Unit I 
CMC,Vellore for his expert opinion ,guidance & valuable suggestions. 
3. Staff of Infectious Disease Clinic & ART centre for helping with recruitment & 
follow up of patients. 
4. Staff of Electrophysiology Lab, Department of Neurology for their constant 
help & cooperation. 
5. My family for their continuous support & encouragement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ACRONYMS 
 
 
ADR Adverse drug reaction 
AIDP Acute Inflammatory Demyelinating  polyneuropathy 
AIDS Aquired Immune Deficiency Syndrome  
ALS Amyotropic Lateral Sclerosis  
ART Anti Retroviral Therapy 
ATT Anti-Tuberculous Therapy  
AZT Zidovudine  
BMI Body Mass Index  
CIDP Chronic Inflammatory Demyelinating  polyneuropathy 
CMAP Compound Muscle Action potential  
CMC Christian Medical College vellore  
CMV Cytomegalo -Virus  
CSF Cerebrospinal Fluid  
D4t Stavudine  
DILS Diffuse Infiltrative Lymphocytosis Syndrome 
DNA Deoxyribonucleic Acid   
DRG Dorsal Root Ganglion  
DSP Distal sensory polyneuropathy  
EFV Efavirenz  
ELISA Enzyme-Linked Immnuosorbent Assay 
ENFD Epidermal Nerve fibre Density  
HAART Highly Active Antiretroviral Therapy  
HIV Human immunodeficiency virus  
I.D.Clinic Infectious Diseases Clinic  
IVIG Intravenous Immunoglobulin 
MM Mononeuritis Multiplex  
NACO National AIDS control Organization  
NCS Nerve Conduction Studies  
NCV Nerve Conduction Velocity 
NNRTI Non-nucleoside Reverse Transcriptase Inhibitor  
NRTI Nucleoside Reverse Transcriptase Inhibitor  
NVP Nevirapine  
PCR Polymerase chain reaction  
PLHA People living with HIV/AIDS  
PP Progressive Polyradiculopathy 
QST Quantitative Sensory Testing  
SNAP Sensory Nerve Action Potential  
TNS Total Neuropathy Score  
 VAS Visual Analog Scale  
3TC Lamivudine  
 
 
 
 
 
LEGENDS  
 
 
   
Figure.1 Pathogenesis of Distal sensory polyneuropathy                                                  Page 18 
 
 Figure 2 –Clinical Approach to  HIV neuropathies                                                         Page  25 
           
  Figure 3: Sympathetic skin response                                                                               Page 31  
 
  Figure 4: ART regimen initiated for enrolled patients                                                    Page 38 
  Figure 5:  New cART regimen during follow up                                                            Page 47 
  Figure 6 : Flow Chart showing study outcomes                                                              Page 49 
 
 
Table 1: Age Category                                                                                                         Page 35  
 Table 2:  WHO clinical stage at the time of presentation                                                  Page 36 
Table 3: Educational status of enrolled patients                                                                  Page 37  
Table 4: Occupation of the enrolled patients                                                                       Page 37 
Table 5: Distribution of patients by tuberculosis                                                                 Page 39  
Table 6: Normative data                                                                                                      Page 40  
Table 7: Electrophysiological characteristics                                                                      Page 41  
Table 8: Types of neuropathy prior to Initiation of cART                                                   Page 43  
Table 9: Risk factors for DSP amongst cART naïve patients                                              Page 43  
Table 10: Change in ART regimen during follow up                                                          Page 46  
Table 11:  Reason for change in the cART  during follow up                                             Page 47 
Table 12: Clinical and Electrophysiological parameters  in                                                Page 50  
                 patients with DSP  
Table 13: Electrophysiological characteristics of DSP on cART                                        Page 52 
Table 14: Abnormal Electrophysiological findings in patients  
                  developing DSP while on first line cART                                                          Page 52  
Table 15: Total neuropathy score                                                                                         Page 53  
 
 
  
CONTENTS 
 
 
1. INTRODUCTION                                                                                      1 
2. OBJECTIVES                                                                                           3 
3. REVIEW OF LITERATURE                                                                     4 
4. PATIENTS AND METHODS                                                                  26 
5. RESULTS                                                                                              35 
6. DISCUSSION                                                                                        55 
7. CONCLUSIONS                                                                                   63 
8. BIBLIOGRAPHY                                                                                   64 
9. ANNEXURES                                                                                       72 
 
 
 
 
TITLE OF THE ABSTRACT: Epidemiology and risk factors of Distal Sensory 
Neuropathy in a cohort of HIV Positive Individuals on first line combination anti-
retroviral therapy – a prospective observational study 
 
DEPARTMENT:  Department of Neurology  
                                                                     :  
NAME OF THE CANDIDATE:  Dr.A.T.Prabhakar 
 
 
DEGREE AND SUBJECT: D.M. Branch I – Neurology 
 
                                                   :  
NAME OF THE GUIDE:  Dr. Mathew Alexander                                              
 
 
       
 
OBJECTIVES:  
To prospectively follow up a cohort of  anti-retroviral therapy naïve HIV infected South 
Indian adults started on  combination anti-retroviral therapy to assess the epidemiology of  
Distal Sensory Polyneuropathy and to assess the risk factors for Distal Sensory 
Polyneuropathy in patients on first line combination anti-retroviral therapy. 
 
METHODS: A cohort of cART naïve  HIV positive patients who have been screened to 
rule out neuropathy using conventional nerve conduction studies were followed up from 
the  initiation of cART  for a  mean period of 59 months. Patients were recruited to the 
study and they were evaluated at base line, three months, six months and then on yearly 
for the development of neuropathy. The assessment was by historical symptoms, clinical 
examination, conventional nerve conduction study and sympathetic skin response. 
 
RESULTS: Of the fifty six cART naive HIV positive patients screened 23.2% of the 
ART were detected to have DSP. The prevalence of symptomatic DSP amongst cART 
naïve patients with HIV was detected to be 5.4%. Low baseline CD4 cell count, 
advancing age, increasing duration of disease and advanced clinical stage of disease were 
identified as risk factors for DSP amongst the cART naive patients. During the follow up 
of forty patients on first line generic cART over a period of 59 months eight patients 20% 
were detected  to have a DSP. The prevalence of symptomatic DSP while on first line 
cART was found to be 7.5%.  The risk factors for the development of DSP while on 
cART were an age greater than 40, a persistently low CD4 count of less than 500 and 
weight loss while on cART.  Absent SSR was associated with symptomatic DSP as well 
exposure to a Stavudine based cART regimen.  
 
 
The global epidemic of HIV is on a steady decline with currently 34 million people 
living with Human Immunodeficiency virus infection(1).   However the number of 
people receiving antiretroviral therapy continues to increase, with 6.65 million people 
getting treatment at the end of 2010(2) . Though India is a country with low HIV 
prevalence, it has the third largest number of people living with HIV/AIDS(3).  As per 
the Indian National AIDS control organisation (NACO)  estimate in 2008-09, there 
are an estimated 23.9 lakh people living with HIV/AIDS(PLHA)  in India with an adult 
prevalence of 0.31 percent in 2009(3).   Neurological manifestations occur during all 
stages of HIV infection and are quite common amongst people living with 
HIV/AIDS(PLHA); of this neuropathy is the most common (4-6). Neuropathies 
complicate all stages of the HIV disease, and cause considerable morbidity and 
disability in HIV infected individuals. The prevalence of symptomatic HIV neuropathy 
has been described between 1.2% to 69.4%(6-8). There are 6 major clinical types of 
HIV-associated neuropathies that are regularly seen in large HIV clinics.(9) Distal 
sensory Polyneuropathy (DSP) is the most common amongst the HIV-associated 
neuropathies(7). DSP usually occurs in later stages of HIV infection and follows an 
indolent and protracted clinical course. The clinical features in DSP include distal 
pain, paresthesia and numbness in a typical length-dependent fashion with proximal 
to distal gradient(8).  Toxic neuropathies-secondary to certain antiretroviral agents-
are clinically similar to DSP, their temporal relation to neurotoxic medication helps 
distinguish them from other HIV associated neuropathies.  
Introduction 
     Antiretroviral toxic neuropathies are commonly  associated with Stavudine , 
zalcitabine and didanosine(10). This has lead to the developed countries avoiding 
the use of these drugs(11, 12). Despite this, until recently  Stavudine had been used 
as the first line therapy in developing countries such as India in view of the low 
cost(13-15). However since January 2013, NACO has initiated the phasing out of 
Stavudine, and new patients who are anaemic (hence cannot be initiated on 
Zidovudine)  are being initiated on Tenofovir.  Data on HIV neuropathy from India is 
very limited. There are no electrophysiological studies on patients with asymptomatic 
DSP.. Wadia et al identified 85 patients with sensory neuropathy in a study of 1527  
HIV infected patients(16) .In another South Indian study by N.Kumaraswamy et al 
involving 1443 patients of  whom 72 % received a D4T based regimen , 13 % had 
adverse events leading to a change in regimen. Of these 15 % was attributed a 
symptomatic peripheral neuropathy (17). In CMC Vellore, in a study involving a 
cohort of 230 HIV infected patients of whom 76 % were on a D4T based regimen 
symptomatic neuropathy was detected in 5.2 %(18). This study thus aims to assess 
the incidence and risk factors for antiretroviral toxic neuropathies, in the setting of 
widespread use of D4T. 
 
 
 
 
 
 
 
 
 
 Objectives of the study 
 
 
1. To prospectively follow up a cohort of  antiretroviral therapy naïve HIV infected 
South Indian adults started on  combination anti-retroviral therapy to assess the 
epidemiology of  Distal Sensory Polyneuropathy  
 
 
2. To assess the risk factors for Distal Sensory Polyneuropathy in patients on first 
line combination anti-retroviral therapy.  
 
 
 
 
 
 
 
 
 
 
 
  
In India the human immunodeficiency virus (HIV) was first detected in Chennai in 
1986 (19).  The subsequent HIV epidemic was fast growing till the year 2000. 
However since then the adult HIV prevalence at the national level has continued  
Review of literature 
its steady decline from estimated level of 0.41 percent  in 2000 through 0.36 percent 
in 2006 to 0.31 percent  in 2009(3).  All the high prevalence states show a clear  
declining trend in adult HIV prevalence. HIV has declined notably in Tamil Nadu to 
reach 0.33 percent in 2009. However, the low prevalence states are now show rising 
trend(3) . The total number of people living with HIV/AIDS (PLHA) in India is 
estimated at 23.9 lakh in 2009(3). The age group 15-49 years contribute to 83 %  
and women contribute to 39% of all the HIV infections. . The four high prevalence 
states of South India (Andhra Pradesh–5 lakhs, Maharashtra–4.2 lakhs, Karnataka–
2.5 lakhs, Tamil Nadu–1.5 lakhs)  account for 55 percent  of all HIV infections in the 
country(3). Of the 2.4 million PLHA in India, more than 20% of these will develop a 
neurological disorder despite the availability of cART(16, 20). HIV causes nervous 
system disease at all the stages of infection with adverse effects on quality of life, 
adherence to medications, employment and survival (20, 21). These disorders 
include in addition to distinct HIV-associated neurological syndromes, opportunistic 
infections  and treatment-related  adverse effects. 
                  Direct HIV infection of central nervous system causes HIV-associated 
neurocognitive disorder (HAND)  and HIV-associated dementia that affect the brain; 
and vacuolar myelopathy that predominantly affects the lateral and posterior 
columns of the spinal cord(22-24).  HIV infection of the peripheral nervous system 
produces a HIV-related neuropathy. There are 6 major clinical types of HIV-
associated neuropathies that are regularly seen in large HIV-1 clinics.(9, 21) Distal 
sensory Polyneuropathy (DSP) is the most common amongst the HIV-associated 
neuropathies(7). With the availability of combination antiretroviral therapy (cART), the 
prevalence of opportunistic infections and AIDS dementia complex has declined and 
DSP has emerged as the single most common AIDS-associated neurologic disorder. 
Most estimates of prevalence of DSP fall between 30% and 60%, but reported 
frequencies vary depending on the diagnostic criteria used and the population 
studied (21) 
 
 
 
 
 
 
 
 
Acute inflammatory demyelinating polyneuropathy 
Human Immunodeficiency Virus–Associated Peripheral Nervous 
System Disorders 
Acute inflammatory demyelinating polyneuropathy, or Guillain-Barré   syndrome,  is 
commonly seen during the phase of seroconversion of HIV infection  and rarely 
during immune reconstitution on initiation of cART(25). It presents as an ascending 
polyradiculoneuropathy within days or weeks(26). It presents as symmetrical 
weakness and areflexia, with or without paraesthesias. Occasionally some  patients  
have a protracted clinical course and are described to have the chronic form, 
namely, the chronic inflammatory demyelinating polyneuropathy (CIDP) (27).  CSF 
findings in HIV-associated acute inflammatory demyelinating  polyneuropathy are 
similar to those noted in patients who are not infected with HIV; however CSF 
pleocytosis can occur, which should alert the clinician to underlying HIV 
infection(28). CSF protein concentrations are often raised, with fewer than 10 cells 
per μL, but up to 50 cells per μL is can  be accepted for diagnosis in patients with 
HIV infection(26). Electrophysiological  findings of early prolongation or absent F-
waves early and prolonged distal latencies,  and slowed conduction velocities and in 
the later stages, are similar to those noted in HIV negative patients with AIDP (26). 
PLHA with GBS respond to treatment well as HIV negative patients.  Sural nerve 
biopsy if done demonstrates the presence of a perivascular and endoneural 
mononuclear cell infiltrate with macrophage-mediated segmental demyelination. In 
severe cases, wallerian-like degeneration of axons can be seen. Treatment does not 
differ on the basis of HIV serostatus, and includes use of plasmapheresis and 
intravenous immunoglobulin(29)  Patients who need mechanical ventilation have 
equally good outcomes in the subset of HIV-infected patients with CD4 cell counts 
greater than 200 cells per μL(30).   Patients with  axonal variant of GBS have also  
been described(31) 
A small subset of HIV-infected patients develop persistent CD8 hyperlymphocytosis 
and a Sjögren’s syndrome–like syndrome associated with multivisceral CD8 T-cell 
infiltration, known as the diffuse infiltrative lymphocytosis syndrome (DILS). These 
patients have higher CD4 cell counts, fewer opportunistic infections, and longer 
survival times than do other HIV-infected patients(32). Some of these patients 
present with an acute or sub acute sensorimotor distal symmetric neuropathy, which 
is always painful(32). In most instances, the neuropathy is distal and symmetrical; 
however, in a third of patients the neuropathy might be focal at onset and progress to 
a multifocal and then symmetrical neuropathy(32). Diagnostic criteria include 
bilateral salivary gland involvement, xerostomia of greater than 6 months duration, 
and histological confirmation of salivary or lacrimal gland CD8 lymphocytic 
infiltration.  Though all patients with diffuse infiltrative lymphocytosis syndrome do 
not have sicca symptoms or parotidomegaly, they characteristically have a 
circulating CD8 hyperlymphocytosis (more than 1000 cells per μL). CSF examination 
reveals an increased protein concentration and mild lymphocytic pleocytosis might 
be noted. Electromyographic and NCS study results are consistent with axonal 
neuropathy. Nerve biopsy shows marked angiocentric CD8 infiltrates without mural 
necrosis and abundant expression of HIV-1 p24 protein in macrophages. The 
lymphocytic infiltrate is polyclonal in most patients (33).  Treatment consists of c ART 
Diffuse infiltrative lymphocytosis syndrome 
and steroid therapy  and was associated with improvement in a small group of 
patients(32). 
 
Chronic inflammatory demyelinating polyneuropathy differs from the acute disorder 
in that it has a more insidious progression (more than 8 weeks) and might relapse 
and remit. It presents as a symmetrical, mainly motor neuropathy in which both 
proximal and distal weakness are more prominent than are sensory findings, but can 
also evolve asymmetrically(27).  Deep tendon reflexes are reduced or absent. 
Sensory complaints include paraesthesias or deep limb pain. Chronic inflammatory 
demyelinating polyneuropathy is probably more common than the acute form(29).  It 
can occur in early HIV infection, but more frequently occurs in moderately advanced 
disease.  Electrophysiological tests reveal demyelinating features such as those 
described for the acute disorder, but could show only subtle slowing of proximal 
conductions . Protein concentrations in the CSF are generally raised, with less than 
50 cells per μL(27). CSF analysis is useful in exclusion of infective or neoplastic 
causes, especially when patients have fewer than 200 CD4 cells per μL.  It is 
Important to note that lymphoma and diffuse infiltrative lymphocytosis syndrome 
neuropathy can  be mistaken as  chronic inflammatory demyelinating 
polyneuropathy. Treatment includes plasma exchange, intravenous immunoglobulin, 
or corticosteroids, and patients often have excellent responses(27). Initiation of 
cART in patients presenting with an immune-mediated disorder is an important 
component of treatment and can hasten recovery.  Responses to treatment in HIV-
infected patients are similar to those in patients not infected with HIV. 
Chronic inflammatory demyelinating polyneuropathy 
 Patients with mononeuritis multiplex present with acute onset of sensory or motor 
deficit limited to one or more peripheral nerve. The asymmetry of involvement is a 
characteristic feature to differentiate it from other HIV-associated neuropathies.  This 
can occur both in the early and late stage. The course is self-limited in early HIV 
infection and is more severe in patients with advanced disease(34).  The CSF 
analysis in these patients is nonspecific and shows only a mild elevation of protein 
concentration and a mononuclear pleocytosis.  Electrophysiologic studies  reveal a 
reduction of the amplitude of sensory nerve action potentials and compound muscle 
action potentials as well as a mild reduction in nerve conduction velocities in the 
distribution of single nerves. Patients with MM can have multiple pathologies on 
nerve biopsy. Axonal degeneration and perivascular inflammatory infiltrates are 
found in patients with early HIV infection or limited clinical involvement. The more 
severe form consists of a necrotizing arteritis with necrosis of endoneurial or 
epineurial vessels suggestive of Vasculitis(35).  Treatment consists of  
plasmapheresis or IVIG (35). Corticosteroids and cyclophosphamide are reserved for 
aggressive cases of MM with vasculitis proved by nerve biopsy. 
Mononeuritis Multiplex 
Patients with progressive polyradiculopathy (PP) present with paresthesia and, 
sometimes radicular pain in the cauda equina distribution. These symptoms are 
followed by a rapidly progressive areflexive paraparesis and ascending sensory loss, 
often accompanied by urinary retention(36). The upper extremities are relatively 
Progressive Polyradiculopathy 
spared. It occurs late in the course of HIV infection, in patients with low CD4 cell 
counts and concurrent systemic illnesses and hence PP is often under 
recognized(36). A prominent infection with CMV, mainly retinitis, oesophagitis, or 
colitis, is conspicuously present in a majority of cases(37).  The CSF analysis 
reveals a marked polymorphonuclear cell pleocytosis, elevated protein 
concentration, and hypoglycorrhachia. CSF cultures demonstrate the presence of 
CMV in 60% of the cases(37, 38). CMV DNA may be detectable in the CSF by PCR 
and  occasionally in blood studies can reveal cytomegalic cells with intranuclear and 
intracytoplasmic CMV inclusions(38). Electrophysiologic studies   reveal reduced 
Compound muscle action potentials (CMAPs) and prolonged F waves.  The 
electromyographic examination is useful to differentiate this syndrome from AIDP. 
Severe and widespread proximal axonal damage in lumbar nerve root distribution is 
correlated by fibrillation potentials and motor unit recruitment patterns in lower 
extremity muscles.  The treatment of CMV-associated PP consists of intravenous 
ganciclovir and/or foscarnet(37). Phenotypic and genotypic characterization of viral 
isolates should be considered in case of resistance to treatment(39). However 
agents such as valaganciclovir and cidofovir have not been evaluated in patients 
with PP.  The results of the PCR for CMV DNA in the CSF may take up to two weeks 
to obtain, in such situations if the workup reveals a polymorphonuclear pleocytosis, 
empiric treatment can be justified.     In disorders predominantly affecting the lower 
limbs tuberculous and lymphomatous meningitis can present as a lumbosacral 
radiculopathy (36, 40). A chronic lumbosacral radiculopathy due to Epstein-Barr-
virus-associated neurolymphomatosis has been reported(29). Lumbosacral 
polyradiculitis can be seen due to reactivation of herpes simplex virus type 2 in the 
sacral dorsal root ganglia after genital herpes, and can even progress to acute 
ascending necrotising myelitis(41).   A case of syphilitic lumbosacral radiculopathy 
has been reported in a patient with HIV infection(42). 
 
Mononeuropathies 
Amongst cranial mononeuropathies, Bell’s palsy is the most commonly seen cranial 
neuropathy in HIV infected patients(21). Such cases of Bell's palsy usually occur as 
peri-inflammatory or post inflammatory palsies around the time of primary HIV 
infection (within 6 weeks pre seroconversion, or in the first weeks of seroconversion, 
respectively).  Recovery is similar to that in patients who are not infected with 
HIV(21). Facial diplegia presenting as a seroconversion illness of aseptic meningitis 
and maculopapular rash have also been reported(43).124 Bilateral facial palsy might  
be the presentation of a descending acute or chronic inflammatory demyelinating 
polyneuropathy(44)  Unilateral or bilateral facial nerve involvement  can occur in 
diffuse infiltrative lymphocytosis syndrome in association with parotidomegaly(28). 
Cranial mononeuropathies in patients who are substantially immunocompromised 
are frequently the result of meningeal infection or lymphomatosis. Lymphoma is an 
important cause of cranial neuropathies; involvement of the facial and trochlear 
nerves and the mental branch of the trigeminal nerve presenting as a numb chin 
syndrome  have been described(45, 46). Tuberculous meningitis commonly affecting 
the  basal cisterns, can produce one or several cranial neuropathies(47). 
Reactivation of dormant varicella zoster virus in the dorsal root ganglia can occur. 
Treatment with aciclovir is indicated in HIV-infected patients. Additional prednisone 
Cranial neuropathies 
can be given to alleviate pain, but does not affect the incidence of post-herpetic 
neuralgia(21). Ramsay-Hunt syndrome, consisting of facial palsy, vertigo, deafness, 
and vesicles c has been reported and  should not be missed(48). Monocular visual 
loss due to rapidly necrotizing varicella zoster virus retinopathy has been reported 
and can easily be misdiagnosed and treated as inflammatory optic neuritis (49). 
 
Entrapment neuropathies of the lateral cutaneous nerve of the thigh, common 
peroneal, median, and ulnar nerves are noted in inpatients with advanced HIV 
disease(21).  whether HIV infection increases the  susceptibility  to get entrapment 
neuropathies in currently  unknown(21). Pressure care in severely ill patients would 
prevent these complications.  Patients with chronic inflammatory demyelinating 
polyneuropathy occasionally present  initially with peroneal mononeuropathies(27). 
Mononeuropathies 
 
Distal sensory polyneuropathy frequently implicates small nerve fiber involvement 
and hence an associated autonomic neuropathy may be expected. However studies 
evaluating the  quantitative measures of autonomic function in HIV-infected cohorts 
have shown  inconsistent results and so far  there has been no evidence of 
significant autonomic dysfunction(27). A community based  study showed that HIV-
infected patients often complained of symptoms possibly related to autonomic 
dysfunction, but objective evidence of autonomic dysfunction was absent(50). 
Autonomic neuropathy 
However, in patients with advanced disease and severe distal sensory 
polyneuropathy, autonomic neuropathic symptoms, such as gastroparesis and 
postural hypotension, have been reported(21). Simple therapeutic measures include 
stopping of potentially exacerbating drugs , supplementation with salt, use of 
fludrocortisone, and wearing of waist-high stockings(21). 
 
HIV-associated neuromuscular weakness syndrome is a subacute progressive 
weakness that is associated with hyperlactataemia and Stavudine exposure and 
presents as a severe, symmetrical, predominantly motor axonopathy with prominent 
leg involvement(51). It is associated  with systemic features such as  nausea, 
vomiting, weight loss, and hepatomegaly(51). High doses of Stavudine doses was 
identified as a possible etiology in the early descriptions, and subsequently has not 
been reported since the standard daily dose was lowered from 60 mg to 40mg. 
Neuromuscular weakness syndrome can be fatal, but most patients recover after 
Stavudine discontinuation. 
HIV-associated neuromuscular weakness syndrome 
.
Myopathy was more common in the era of HAART when high dose Zidovudine was 
widely used(52). With the reduction of the dose of zidovudine, the incidence of 
Zidovudine induced myopathy has declined.  HIV infection per say is associated with 
a Polymyosits type of myopathy and can be clinically similar to Zidovudine induced 
myopathy(53).  Patients usually present with a proximal symmetric weakness, 
predominantly  at the level of the hip flexors(54). HIV-1 does not seem to infect 
Myopathy 
muscle fibers, but muscle fibers are Infiltrated predominantly with CD8+ T cells and 
macrophages(53). It is postulated that  these cells secrete proinflammatory cytokines 
that may damage muscle fibers, precipitate muscle antigen exposure, and generate 
an autoimmune response(55). Zidovudine-induced myopathy is due to mitochondrial 
toxicity; this in turn is mediated through the inhibition of the enzyme γ-DNA 
polymerase, which is responsible for the replication of mitochondrial DNA. This 
induces an energy shortage within the muscle, which results in overt myopathy over 
time. The laboratory Investigations reveal a mild elevation of creatine phosphokinase  
with its level correlating with the degree of myonecrosis seen on muscle biopsy; but 
not with the weakness. Electromyographic testing may reveal myopathic motor unit 
potentials with early recruitment and full interference patterns, predominantly in 
proximal muscles(54), but it can  be normal in one third of the cases(52). Muscle 
Biopsy in patients not treated with zidovudine presenting with myopathy, the most 
common finding is scattered myofiber degeneration, fibrosis,  and necrosis, 
associated with a variable inflammatory infiltrate similar to that seen in idiopathic 
polymyositis(56), In zidovudine myopathy, biopsy results reveal numerous ragged-
red fibers and abnormal mitochondria(56). Treatment of HIV polymyostis is similar to 
idiopathic polymyositis and patients have had a favorable response with 
corticosteroids. Other immune-based therapies such as azathioprine, methotrexate, 
or IVIG have also been successful(52). In zidovudine-induced myopathy, treatment 
consists of zidovudine withdrawal; with which most patients respond within few 
weeks(56).  
 
 
 There are several cases of amyotrophic lateral sclerosis (ALS)-like syndromes  
reported in HIV-infected individuals(57). These cases differ from classic ALS 
because they occurred in younger patients, they were unusually rapidly progressive, 
and improved after the institution of antiretroviral therapy(57, 58). The etiology of this 
syndrome is unclear. 
Amyotrophic Lateral Sclerosis–Like Syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
Distal Sensory Polyneuropathy 
Distal sensory polyneuropathy (DSP) is the most common cause of peripheral 
neuropathy in HIV infection.  The prevalence of symptomatic HIV neuropathy has 
been described  between  10% to  60 %(7, 8) . Of this it is symptomatic in 35% of 
patients and asymptomatic in an additional 20%(59). In autopsy studies it is seen in 
most patients dying with AIDS(60).  
Human Immunodeficiency Virus Associated 
Risk factors for DSP 
This condition occurs generally in patients with advanced immunosuppression. 
Studies done in the  pre-HAART era revealed that DSP was associated with 
advancing age(61), high plasma viral load (62)and low CD4 cell counts(59). Recent 
studies show that there is an association with age but plasma viral load and CD4 cell 
counts have no association(63). Hence it is postulated that previously reported 
virologic and immunologic associations of DSP may be affected by cART(63). Also 
there is preliminary data to suggest that there are ethnic disparities in the clinical 
manifestations of DSP(64).  
Nerve biopsies from patients with DSP reveal of axonal degeneration of myelinated 
and unmyelinated axons. Punch skin biopsies show evidence of reduced 
intraepidermal nerve fiber density in the distal leg(65). Also  dorsal root ganglion 
(DRG) neuronal loss has been demonstrated in DSP(66). The pathogenesis of DSP 
is currently unknown. There is no evidence of direct infection or viral replication in 
Pathogenesis 
the neurons; however the virus is limited to monocyte/ macrophages. There are 
inflammatory infiltrates around peripheral nerve fibers and in the DRG consisting of 
activated macrophages. These activated macrophages  release  cytokines such as 
TNF-α, interferon-γ, and IL-6(60).  The presence of activated macrophages secreting 
inflammatory cytokines, rather than the virus itself, seems to account for most of the 
peripheral nerve damage(67).  How activated macrophages penetrate DRG and 
peripheral nerve fibers is unclear, and it has been hypothesized that the blood-nerve 
barrier may be affected in HIV-infected patients(60). It has been  demonstrated that 
deposition of TNF-alpha in peripheral nerves correlates with neuropathy(68) . It is 
postulated that binding of gp120 on the  Schwann cell chemokine receptor CXCR4 
results in the release of RANTES, which induced dorsal root ganglion neurons to 
produce tumor necrosis factor-alpha and subsequent TNFR1-mediated neurotoxicity 
(69). Also by acting directly on axons, gp120  can induce further axonal degeneration 
independently of inflammatory intermediators(70) Binding of gp120, Vpr, and 
possibly other viral proteins to neuronal chemokine receptors results in neuronal 
hyperexcitability and painful symptoms. In a recent study involving a rhesus 
macaque model for HIV neuropathy, the dorsal root ganglion involvement was 
studied in SIV-infected CD8 T-lymphocyte-depleted macaques, where activation of 
endogenous CD68+ macrophages was found to perpetuate the DRG damage and 
neuronal loss as evidenced by  neuronophagia and formation of Nageotte 
nodules(71). 
 
 
Figure.1 Pathogenesis of Distal sensory polyneuropathy
 
(21) 
 
Clinical Presentation 
DSP is characterized by the progressive onset of symmetric paresthesias, 
numbness, and painful dysesthesia of the lower extremities. The pain is often 
described as an aching or burning sensation and is worse on the soles of the feet. 
Symptoms may remain stable or progress over months or years and ascend in a 
length-dependent fashion up the legs(8).. Most patients complain of a maximal 
discomfort when they are barefoot in bed. Therefore, DSP may have a major 
negative impact on the patient’s ability to ambulate and the quality of their sleep. 
Perception of noxious stimuli, temperature, and vibrations is usually more affected 
than light touch and proprioception(61). Hyporeflexia of the lower extremities is a 
very common finding, and gait ataxia with positive Romberg sign is present in severe 
cases. Weakness is rarely found on the examination or is confined to the intrinsic 
foot muscles. 
Laboratory Investigations 
CSF analysis shows only nonspecific findings with mild elevation of protein 
concentration and mononuclear pleocytosis, which is common in HIV-1 infection. 
Electrophysiologic Studies 
Nerve conduction studies (NCS) show low-amplitudes, CMAPs and SNAPs(8). 
Sensory and motor nerve conduction velocities are normal or only mildly reduced. 
Electromyographic studies demonstrate acute denervation and chronic re-
innervation in distal leg muscles. These findings are consistent with an axonal distal 
symmetric, predominantly sensory, polyneuropathy(8). 
Skin Biopsy 
Skin biopsy and Epidermal nerve fiber density(ENFD) have been described as useful 
diagnostic tools for HIV related DSP(5, 65). Also ENFD correlated well with severity 
of symptoms and predicted the progression from asymptomatic to symptomatic 
DSP(72). A leg ENF density of 10 fibres/mm was associated with transition from 
asymptomatic to symptomatic DSP within the next 6 to 12 months(73). 
 
 
 
 
DSP as a  result of the  neurotoxicity of NRTIs zalcitabine (ddC), didanosine (ddI), 
and stavudine (d4T) has been commonly described(10, 74).  The risk is increased in 
patients using regimens containing a combination of ddI and d4T(75).The clinical 
presentation and electrophysiologic studies are indistinguishable from DSP.  The 
timing of nucleoside neuropathy is variable.  With the discontinuation of the offending 
medication the pain usually resolve within 8 – 16 weeks, but the signs of neuropathy 
may remain much longer. However this improvement  it is often preceded by a 
transient worsening of symptoms known as “coasting.”(76) 
Nucleoside Neuropathy 
              The pathogenetic mechanism of nucleoside neuropathy appears to be most 
likely related to nucleoside induced mitochondrial dysfunction; this in turn is 
mediated through the inhibition of the enzyme γ-DNA polymerase, which is 
responsible for the replication of mitochondrial DNA. Raised plasma lactic acid 
concentration  an indicator of mitochondrial dysfunction was useful in discriminating 
between d4T nucleoside neuropathy and DSP with 90% sensitivity and 
specificity(77). Nucleoside neuropathy occurs more frequently in individuals with 
preexisting DSP. These data suggest that dNRTI may only exacerbate an 
inflammatory process triggered by activated macrophages in peripheral nerve fibers 
or DRG of HIV-infected individuals. In the dorsal root ganglion, dNRTIs are 
associated with upregulation of chemokines and chemokine receptors, contributing 
to the inflammatory background.  Also mitochondrial abnormalities are much lesser 
compared to nucleoside neuropathy was seen in neuronal culture with the addition of 
gp120 alone. Hence it postulated that  that there may be synergistic effects between 
HIV and the dideoxynucleosides on mitochondria.(78).   Genetic association studies 
have identified genes affecting mitochondrial function and genes involved in the 
inflammatory response that modify the risk for HIV-SN among patients exposed to 
neurotoxic antiretrovirals (79) 
 
Multiple comorbid factors may predispose or potentiate distal sensory 
polyneuropathy. Older age (>40 years) has been identified factor as the most 
consistent factor (61).  Individuals who are tall have Increased risk for both 
symptomatic and asymptomatic distal sensory polyneuropathy(80, 81). Tall people,  
have longer peripheral nerves and it has been established that mitochondrial DNA 
mutations accumulate with increasing distance from the cell body(82). Variations in 
several genes encoding inflammatory factors and mitochondrial haplogroups are 
associated with a predisposition for DSP.  Associations with advanced HIV infection, 
lower CD4 cell counts, and high viral loads have been noted, but are not prominent 
in the post cART era. Diabetes mellitus, a frequent cause of sensory neuropathy in 
the general population, might increase risk for distal sensory polyneuropathy and can 
be used to predict the development of symptoms in those with asymptomatic DSP 
while on cART(81). Also, increased concentrations of serum triglycerides, another 
component of the metabolic syndrome, has been independently associated with 
DSP(83). These risk factors are becoming increasingly important as the  cART 
improves survival and the population ages. In HIV-infected people, malabsorption, 
inadequate nutritional intake, and changed metabolism might lead to micronutrient 
deficiencies(84) However,  till date  only vitamin B12 deficiency has been associated 
with distal sensory polyneuropathy(84).  Isoniazid(INH) is a core component of the 
Co-morbid factors  
Anti-tuberculosis treatment(ATT) regimen  and can produce pyridoxine deficiency 
and a sensory neuropathy very similar to that of DSP(85). HIV-infected patients 
receiving Isoniazid have a  greater risk of developing neuropathy than are TB 
patients who are not infected with HIV, and these patients can develop INH induced  
neuropathy despite pyridoxine supplementation, possibly  due to pre-existing 
deficiency or  due to a low threshold for neurological injury(86). Also  co-infected  
patients with HIV and  tuberculosis can have DSP symptoms even before 
tuberculosis treatment is started due to unmasking of subclinical distal sensory 
polyneuropathy. It has been shown that INH may increase the risk for antiretroviral 
toxic neuropathy(87). Protease inhibitors, such as indinavir,  is neurotoxic  and might 
contribute to the development of distal sensory polyneuropathy(88).  The use of 
protease inhibitors increases the odds for DSP  only in patients who   receive 
concomitant dNRTIs.   Alcohol is another important determinant factor in the 
pathogenesis of DSP due to its synergistic mitochondrial toxic effect with dNRTIs 
(89).  Multiple substance abuse such as  alcohol, cocaine, cannabis, and stimulants 
may contribute to DSP and the risk increases with the number of substances 
used(89).  Hepatitis C virus infections can cause neuropathy; however, most studies 
have not shown co-infection with Hepatitis C  to be an independent risk factor for 
DSP(90). DSP is more frequent in patients co-infected with HIV and HTLV-1 and 
HTLV-2  (91, 92).  
 
 
 
Treatment of HIV neuropathy 
The treatment of neuropathic pain in DSP is purely symptomatic as the damage to 
the nerve fibers and DRG is irreversible. Hence therapy is aimed primarily at 
attenuating the pain and improving the quality of life of these patients. First-line 
therapies include nonsteroidal anti-inflammatory drugs and acetaminophen but they 
may not be beneficial in all patients.  
                   Anticonvulsant medications have been used successfully for neuropathic 
pain in other painful neuropathies and has been found to be useful in HIV related 
DSP. However medications such as carbamazepine and phenytoin are 
contraindicated in DSP because both are metabolized by the liver, and may cause 
unwanted drug interactions. Gabapentin is metabolized by the kidneys and is usually 
well tolerated by HIV-infected individuals(93).  A trial evaluating lamotrigine in HIV 
positive patients with symptomatic DSP, showed a substantial pain reduction in a 
subgroup of patients receiving neurotoxic NRTIs but there was  no difference 
compared with placebo in patients with DSP who were not on nucleosides(94). 
Amitriptyline, which is commonly used for the treatment of diabetic neuropathy, was  
not superior to placebo in HIV-infected patients with DSP(95). 
 
                 Topical therapy for DSP has received a lot of attention recently. The 
topical application of capsaicin(96) and  5% lidocaine gel(97) have been found to be 
beneficial. A higher dose of capsaicin has been tried as a transdermal patch and was 
found successful(98). The mechanism of action of capsaicin has been studied 
extensively. Application of capsaicin causes an almost complete depletion of the 
Intra epidermaI nerve fibers (IENF), however within the next 27 days there is 
regeneration and repletion of these fibers. This effect is thought to be mediated by 
capsaicin stimulating the depletion of substance P, neurokinin, somatostatin, and 
calcitonin from peripheral nerve fibers, particularly C-fibers (99). 
 
                      Narcotic analgesics should be kept as last resort because of their 
addictive potential in the context of a chronic pain syndrome. Tramadol shares 
properties with opioid analgesics but is less likely to cause dependence and lead to 
abuse(95). Long-acting opioid agonists such as fentanyl patches should be preferred 
to short-acting agents. A recent trial looking at Smoked cannabis in HIV associated 
DSP revealed that  smoking cannabis  effectively relieved chronic neuropathic 
pain(100). 
                   Numerous experimental drugs have been disappointing in the treatment 
of DSP, including mexiletine, peptide T, recombinant human nerve growth factor, 
plasmapheresis, and acupuncture(101). Depletion of acetyl carnitine, a substrate in 
the β-oxidation of free fatty acids, was implicated in the pathogenesis of 
DSP(102),but this was not confirmed in a larger study(103). Newer therapies using 
neuroimmunophilin ligands and prosaposin are currently under investigation(104). In 
the mouse model supplementation of uridine was shown to reverse the toxicity of 
nucleoside antiretroviral drugs however this awaits further clinical research (105). 
Currently there are no specific prevention measures available for DSP.  However 
provision of multivitamin supplementation to all HIV-infected patients seems prudent. 
Pyridoxine should be given to patients receiving isoniazid(85). Initiation of cART at 
CD4 cell counts of more than 200 cells per μL might be protective. Older patients (ie, 
those older than 40 years) and those with pre-existing distal sensory polyneuropathy  
should receive non-neurotoxic cART(81). These patients can be identified through 
routine clinical screening74 or through a simple questionnaire about neuropathic 
symptoms(106).  
 
 
Figure:2 –Clinical Approach to Diagnosis and Management of motor and 
sensorimotor neuropathies associated with HIV infection 
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 PATIENTS AND METHODS 
 
The study was conducted in Christian Medical College Hospital Vellore, a 1800 
bedded academic medical centre in South India. Eligible subjects were recruited 
from the Infectious Disease Clinic which is a dedicated Outpatient service for People 
Living with HIV/AIDS (PLHA). The clinic provides comprehensive and holistic care 
for PLHA. The average attendance is around hundred patients per outpatient clinic.   
Study Setting: 
 
 
Study Design
A prospective cohort study  
: 
The study design and methods were approved by the Institutional Review Board of 
Christian Medical College, Vellore. 
  
 
 
 
  
Participants 
 Adult patients (aged 18 years or over) with HIV infection on follow up with the 
Infectious diseases clinic. 
 
 
  
Adult patients (> 18 years) with HIV infection on follow up in the ID clinic with 
the following.  
Inclusion Criteria: 
(1) HIV confirmed by dually reactive ELISA test  
(2) Subjects were residents of South Indian states ( Tamil Nadu, Andhra 
Pradesh, Kerala and Karnataka 
(3) All subjects satisfied the medical eligibility for initiation of antiretroviral 
therapy (WHO stages III/IV or WHO stage I/II with CD4 counts less than 200 
cells / µL. 
(4) The Subjects had to be ART naïve( Defined as having received less than 
four weeks of ART prior to enrolment) 
(5) Willingness to participate in the trial 
(6) Willing to come for follow up after three months and six months. 
 
 
 
 
Exclusion Criteria: 
(1) Patients with diabetes mellitus requiring  oral hypoglycaemic agents  or insulin 
(2) Patients with Vitamin B12 levels < 200 pg/ml. 
(3) History of exposure to neurotoxins-  
 Organophosphates- History of being involved in spraying pesticide,     
   History of consuming OP any time in the past 
Siddha medicines - History of taking Siddha medicines within the past        five 
years 
(4) Alcoholism –  as defined as greater than 30 drinks per week 
(5) History of Hansen’s disease in the past  as evidenced by  patient reporting / 
documents/ clinical examination 
(6) Diagnosed peripheral nerve disease 
(7) Patient not willing to participate 
 
 
Withdrawal criteria: 
 Patient unwilling to continue participation in the study. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Subject Enrolment 
ART-naïve HIV infected adults, eligible for or being initiated on HAART were 
considered for screening. If the patient fulfilled the necessary criteria for inclusion, 
then they were approached for informed consent.  If the patient consented clinical 
and demographic data were collected and then the patient underwent a standardised 
neurological examination with emphasis on peripheral nerve function.  All patients 
underwent Nerve conduction studies (NCS) with standardised anatomical landmarks.  
Electrophysiological testing: Median, ulnar and peroneal motor fibers, median and 
ulnar sensory fibers, superficial peroneal nerves and sural nerves were studied. The 
compound muscle action potentials (CMAPs) were recorded with surface recording  
electrodes, which were placed over the main bulk of abductor pollicis brevis, 
abductor digiti minimi and extensor digitorum brevis for the median, ulnar and 
peroneal nerves respectively. A bipolar percutaneous stimulator was located at the 
wrist 7 cm proximal to the active recording electrode for median and ulnar motor 
NCS. Proximally the median nerve was stimulated just medial to the biceps tendon 
at the elbow crease and the ulnar nerve was stimulated above the elbow. The 
stimulation was delivered between the tendons of tibialis anterior and extensor 
hallicis longus muscle 9 cm proximal to the active recording electrode. A 
supramaximal stimulation of 0.1 ms duration was delivered for all the motor NCS. F 
waves were obtained at the distal motor stimulation point and the minimal latency of 
10 consecutive stimulations was recorded. Only deflections larger than 50 μV were 
accepted, to differentiate F waves from background noise. The sensory nerve action 
potentials (SNAP) were recorded by orthodromic techniques in the upper limbs and 
antidromic  techniques in the  in the lower limbs. The stimulating electrode was 
placed on the 2nd and the 5th digit for median and ulnar nerves respectively with 
recording 13 cm proximally from the wrist just medial to the flexor carpi radialis 
tendon for the median nerve and 11 cm proximally just posterior to the flexor carpi 
ulnaris tendon for the ulnar nerve. The recording electrode for sural nerve studies 
was placed behind the lateral malleolus and it was stimulated in the mid-calf 14 cm 
proximal to the active recording electrode. The recording electrode for superficial 
peroneal nerve was placed at the level of ankle midway between the edge of the 
tibia and the tip of the lateral malleolus and the nerve was stimulated by electrodes 
placed 14 cm proximal to active recording electrode.  All SNAP's were recorded 
using 0.1 ms stimulus duration. Filter settings were 2Hz and 10 kHz for motor studies 
and 20 Hz and 2 kHz for the sensory studies. The latencies were measured from the 
onset of the action potential. The amplitudes were measured from peak to peak for  
both CMAPs as well as SNAPs.  The distance between the distal and proximal 
stimulations was recorded for motor nerve conduction velocity (NCV) determination. 
Sensory nerve conduction velocities were calculated from the onset latencies. The 
ground electrode was placed between the stimulation and recording electrodes for all 
studies. The room temperature was kept at 26 C.    SNAPs were classified as 
abnormal if the measured amplitude was less than 50 % of the lower limits of normal. 
The normative data used in the diagnosis is given in Table: 6. The Cut off value for 
superficial peroneal SNAP was taken and 10µV. 
 
 
 
 
 
Sympathetic Skin Response 
For recording the SSR, the active electrodes were placed in the palm and sole with 
the reference over the dorsum of the respective body part, after cleaning the skin 
surfaces and using electrolyte gel. The patient was asked to lie supine and relax.  
The low-frequency filter was kept at 0.5 Hz and the high-frequency filter was kept at 
of 500 Hz.  The stimulus was an electrical shock delivered to the median nerve  
On the side opposite to the recorded site. The electrical stimulus was applied as  a 
single square pulse, 0.1–0.2 ms in duration.  The stimulus intensity ranged between 
10 and 30 mA, to get a strong but tolerable response. The amplitude was measured 
from peak to peak and expressed in microvolt. The response was considered absent 
if no consistent voltage change occurred using a sensitivity of 50 µV per division 
after 3 trials at maximum stimuli intensity. 
 
 
Figure 3: Sympathetic skin response 
 
Typical sympathetic skin response 1- in upper limbs , 3 – in lower limbs  
 
 
 
Assessment of symptoms   
If the patients were symptomatic, the measure of pain was assessed by the visual 
analog scale (VAS). The patients were reviewed at three months, six months and 
then on yearly till March 2013. At this point the detailed neurological evaluation and 
electrophysiological testing was repeated for all the patients and the Total 
Neuropathy Score was calculated. 
 
Variables 
General  
1. Demographic data  
2. Baseline anthropometric data – height, weight, body mass index. 
3. Baseline CD4 count and serial CD4 counts 
4. Plasma viral load (if available) 
5. ART regimen being initiated  
6. Opportunistic infections in the past and on follow up  
7. Drug and treatment history  
8. Assessment of adherence and drug toxicity  
 
Assessment of neuropathy  
1. Assessment of pain by VAS 
2. Detailed neurological examination 
3. Conventional nerve conduction studies  
4. Sympathetic skin response  
5. Total neuropathy score (TNS) 
 
 Study outcome 
Neuropathy as defined as clinical or electrophysiological evidence of peripheral 
nerve dysfunction:  
1. Sensory symptoms suggestive of peripheral neuropathy 
2. Sensory examination suggestive of peripheral neuropathy 
3. Tendon reflexes suggestive of a neuropathy 
4. SSR if done showing absent response  
5. NCV/EMG  suggestive of neuropathy  
 
 A subject is defined as having symptomatic DSP if the sensory symptoms are 
present and at least two of four remaining key components (sensory function, tendon 
reflexes, NCV, and  SSR) are abnormal, with at least one of the abnormal 
components being either NCV or SSR. 
Symptomatic DSP: 
 
 Asymptomatic DSP
 
: A subject is defined is having Asymptomatic DSP if  the 
sensory symptoms component was normal and at least one of four remaining key 
components(sensory function, tendon reflexes, NCV, and SSR) were abnormal, with 
at least one of the abnormal components being either NCV or SSR. 
 
 
 
 
1.  Neuropathy warranting change of antiretroviral therapy regimen  
Secondary Outcomes 
2.  Ascending neuromuscular weakness developing after initiation of ART 
3.  Patient developing Peripheral nervous system involvement other than DSP while 
on ART as evidenced by clinical and electrophysiological examination  
4. Acute inflammatory Demyelinating polyradiculoneuropathy (AIDP) - as diagnosed 
by standard diagnostic criteria  
5. Chronic inflammatory Demyelinating polyradiculoneuropathy (CIDP) as diagnosed 
by standard diagnostic criteria 
6. Immune reconstitution syndrome – presenting with Peripheral nervous system 
involvement  
 
 Data entry was done using SPSS software (version 15.0). Descriptive statistics were 
calculated using SPSS software. The Chi-Square test was used for the comparison 
of categorical variables, and the student t test was used for the comparison of 
continuous variables.  Odds Ratio (OR) and confidence intervals (CI) were 
calculated and,  ‘P’ value less than 0.05 was considered statistically significant.  
Univariate logistic regression analysis was used to determine the risk factors for the 
development of HIV neuropathy.  
Analysis:  
 
 
 
 
 
  
RESULTS 
 
Baseline characteristics  
A total of 56 consecutive ART naïve patients were screened for neuropathy using 
clinical and electrophysiological criteria. 16 patients were identified to have evidence 
of clinical or electrophysiological evidence of peripheral nerve disorders and were 
excluded from the study.  40 patients who were initiated on cART had normal clinical 
and electrophysiological finding and were enrolled into the study and followed up for 
a median period of 59 months.  
The baseline characteristics of the patients are as listed below: 
The study population comprised of 60% males and 40% females. The mean age of 
the study population was 37.5 years (mean (S.D), 37.5(±7.4) 
 
Table 1: Age Category 
 
Age Category Frequency Percent 
20 - 30 
  
31 - 40 
  
41 - 50 
  
51 - 60 
  
Total 
8 20.0% 
21 52.5% 
9 22.5% 
2 5.0% 
40 100.0% 
 
 
 
 
The mode of acquisition of HIV infection was heterosexual in all the patients. Majority 
of the patients had advanced stages of HIV infection belonging to either WHO 
clinical stage III or IV (65%) the distribution was as follows: 
 
 
Table 2:  WHO clinical stage of illness at the time of presentation to I.D clinic  
 
WHO clinical stage Frequency Percent 
WHO stage I 
 
WHO stage 2 
 
WHO stage 3 
 
WHO stage 4 
 
Total 
7 
 17.5% 
6 
 15.0% 
25 
 62.5% 
2 
 5.0% 
40 100.0% 
 
 
          Of the patients enrolled, a larger proportion (66%) were within one year from 
the diagnosis if HIV infection. Most of the patients were married (90%) and most of 
them had completed at least primary education (87.5%).  
All patients were functionally independent and were employed at the time of 
enrollment. Fifteen (37.5%) patients, all of whom were males were in the habit of 
smoking tobacco.  
 
 
 
 
 
 
 Table 3: Educational status of enrolled patients  
  
  
  
Education 
 Frequency Percent 
 
Illiterate 
  
primary school 
  
secondary school 
 
 college 
 
 Total 
 
5 12.5% 
13 32.5% 
21 52.5% 
1 2.5% 
40 100.0% 
 
 
 
 
Table 4: Occupation of the enrolled patients  
  
Occupation 
 Frequency Percent 
Home maker 
  
Manual labourer 
  
Driver 
  
Agriculture  
  
Businessman 
  
Total 
9 22.% 
15 37% 
6 15% 
2 5% 
8 20% 
40 100% 
 
 
 
 
 
  
 The mean CD4 cell count prior to initiation of cART was 165 (± 77.17) cells / µL and 
the values ranged between 24 to 336  cells / µL.  Eight patients (20%) had a baseline 
CD4 count less than 100 cells / µL.  
Baseline CD4 cell counts 
 
 
Figure 4: ART regimen initiated for enrolled patients at I.D.Clinic 
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AZT/3TC/EFV
D4T/3TC/NVP
D4T/3TC/EFV
ART Regimen
Pies show counts
AZT/3TC/NVP
32.50%
13.0
AZT/3TC/EFV
5.00%
2.0
D4T/3TC/NVP
50.00%
n=20
D4T/3TC/EFV
12.50%
5.0
Stavudine based regimen was used in 25 ( 62.5%) patients and Nevirapine based 
regimen was used in33( 82.5 %) patients.  
Nine patients (22%) had  of tuberculosis  and were on ATT at the time of initiation. 
All patients were on replacement of 10 – 20 mg of pyridoxine daily.  
 
Table 5: Distribution of patients by tuberculosis 
   
Tuberculosis 
 Frequency Percent 
No history of tuberculosis 
  
Sputum positive pulmonary tuberculosis 
  
sputum negative pulmonary tuberculosis 
  
Disseminated Tuberculosis 
  
Tuberculosis Meningitis 
 
  
Tuberculous Lymphadenitis 
  
Total 
 
31 77.5% 
1 2.5% 
1 2.5% 
1 2.5% 
2 
 5.0% 
4 10.0% 
40 100.0% 
 
One patient had pneumocystis  jerovici pneumonia and one patient had CMV 
retinitis. Two patients has chronic diarrhea secondary to Isospora infection. 
 
 
 
 
 
 
 
 
All patients underwent a detailed clinical and Neurological examination. The mean 
weight of the patients was 54.5(±10.3) and the mean BMI was 20.25 (± 3.2). On mini 
mental status examination, the mean was 27.5 (±0.8).Three patients had positive 
sensory symptoms in the glove and stocking pattern. The complaints were of burning 
paraesthesias over the soles of the feet. There were no autonomic symptoms. There 
was no sensory ataxia.  Except for three patients, all patients had a normal systemic 
and neurological examination. Sensory loss detected on monofilament and vibrations 
testing along with hyporeflexia were the abnormal neurological findings detected.  
Baseline Clinical and Neurological Examination  
Electrophysiological Characteristics
All Patients underwent conventional nerve conduction studies of both the median, 
ulnar, peroneal and sural nerves at the baseline.  During follow up all patients had a 
six monthly clinical examination followed by selective electrophysiological testing for 
symptomatic patients. All patients had a detailed clinical and electrophysiological 
testing at the end of the study period.  The normative data is as follows. 
: 
Table 6: Normative data  
Nerve 
 
 
 
 
Distal 
latency 
 
m.sec 
Amplitude 
 
mV/µV 
 
Conduction 
velocity 
M / sec 
 
F wave 
 
m.sec 
Median motor 3.12 [+/-0.62] 12.0[+/-5.0] 54.9[+/-10.9] 26.6[+/-3.5] 
Median sensory 2.27[+/-0.44] 25.6[+/-10.0] 57.4[+/-11.9]  
Ulnar motor 2.17[+/-0.55] 9.0[+/-3.0] 59.4[+/-10.9] 26.6[+/-3.5] 
Ulnar sensory 1.8[+/-0.62] 20.4[+/-9.6] 56.4[+/-10.7]  
Peroneal 3.56[+/-1.22] 8.0[+/-2.62] 46.5[+/-7.78] 47.8[+/-5.9] 
Sural 2.36[+/-0.62] 8.0[+/-2.62] 48.2[+/-9.8]  
 
 
Table 7: Electrophysiological characteristics  
Upper limbs 
Right Left 
Mean Std. Dev Mean Std. Dev 
Median Nerve  
Motor (CMAPs) 
millivolts 
14.9179 4.03080 15.3875 4.61842 
Sensory(SNAPs) 
Microvolts 
30.3393 10.96486 31.1250 10.22486 
Distal Latency 
(milli seconds) 
3.2970 .57745 3.1264 .53002 
F wave Latency  
(milli seconds) 
26.4839 2.26890 26.4250 2.59932 
Cond.Velocity 
m/s 
56.5179 9.60687 56.2607 7.40058 
Ulnar Nerve 
Motor (CMAPs) 
millivolts 
14.2643 3.06122 13.4696 3.18296 
Sensory(SNAPs) 
Microvolts 
25.3214 8.61311 24.5714 8.30741 
Distal Latency 
(milli seconds) 
2.5254 .44012 2.5630 .44150 
F wave Latency  
(milli seconds) 
26.7161 2.41516 26.6321 2.59469 
Cond. Velocity 
m/s 
59.2018 6.69715 59.5839 9.87435 
 
 
 
 
 
 
 
Table 7: continued  
 
Lower Limbs  
Right Left 
Mean Std. Dev Mean Std. Dev 
Peroneal Nerve 
Motor (CMAPs) 
millivolts 
8.5446 4.20890 8.1268 3.81716 
Distal Latency 
(milli seconds) 
3.3868 .44203 3.4796 .54604 
F wave Latency 
 (milli seconds) 
 
47.4929 5.79755 47.7429 5.98452 
Conduction Velocity 
m/s 
48.2107 5.69008 48.4054 6.86762 
Sural Nerve 
Sensory(SNAPs) 
Microvolts 
26.7321 16.87008 26.0446 14.17240 
 
Types of HIV Neuropathy Based Electrophysiological studies 
  On screening 56 patients with clinical and electrophysiological testing 13 patients 
were identified to have a peripheral nerve disorder.  Eleven of the thirteen patients 
(84.6%) had an axonal, length dependent neuropathy and two patients had a 
mononeuritis multiplex pattern. Two patients had features of carpal tunnel syndrome. 
The patients with neuropathy that was present prior to initiation of cART were 
considered to have HIV neuropathy or viral neuropathy and were excluded from 
further analysis and follow up. On univariate analysis, advanced age, clinical stage of 
disease and a low CD4 count were identified as risk factors for HIV neuropathy in 
ART naïve patients being initiated on ART.  
 
Table 8: Types of HIV neuropathy detected on Electrophysiology prior to 
Initiation of cART ( n=56) 
Electrophysiological Type Frequency Percent 
Motor sensory axonal neuropathy  7 53.8% 
Sensory neuropathy 2 15.4% 
Polyradiculoneuropathy 2 15.4% 
Mononeuritis multiplex 2 15.4% 
Carpal tunnel syndrome 2  
Total  13 100% 
 
 Two of the patients without HIV neuropathies were detected to have an 
asymptomatic carpal tunnel syndrome (CTS). Both these patients were negative for 
Hansen’s disease but one was detected to be a diabetic on diet. They were clinically 
euthyroid but thyroid functions were not tested. The patients with CTS were not 
included in the analysis.  
Table 9: Risk factors for DSP amongst cART naïve patients  
 Predicting variable Odds Ratio 95% CI P value 
1 Age > 40 years  3.692 1.013 -13.455 0.05 
2 Disease duration > 2 years 7.425 1.879 - 29.336 0.006 
3 WHO clinical stage 3 or 4 1.448 1.183 -1.773 0.025 
4 CD4 < 100 cells / µL 4.407 1.183 -16.414 0.035 
  
A total of 120 median, ulnar and peroneal nerves were studied. The peroneal nerve 
was the commonest nerve affected, followed by the median and ulnar nerves.  There 
was no differential involvement between the median and ulnar nerves.  
Reduction in CMAPS was seen in 11 patients and the reduction in SNAPS was seen 
in 13 patients. There were no conduction blocks. For patients with electrophysiology 
suggestive of a polyradiculoneuropathy, the modified Cornblath criterion was used 
for the diagnosis of CIDP. However none of the patients fulfilled the criteria(107).  
                   The severity of the axonopathy was more in the peroneal nerves than 
compared to ulnar or median. Of the lower limb nerves tested, the Peroneal was 
more involved than the tibial nerve.  Amongst the thirteen patients with HIV 
neuropathy eight patients had involvement of the tibial nerves; of these, in five 
patients the drop in CMAPs was less as compared with the concomitant peroneal 
nerve.  Fifteen patients (27%) had prolongation of the F waves.  The prolongation of 
F waves was seen in 15 % of the upper limbs and 22 % of the lower limbs.  Of the 
sensory nerves tested the sural nerve was more involved than the median and ulnar 
nerves. The severity of the drop in SNAPs did not correlate with clinical symptoms, 
duration of disease, CD4 counts or WHO stage of disease.  The cohort of 40 patients 
who were negative for neuropathy and were initiated on cART were followed up six 
monthly till march 2013.  
 
 
 
 
 
 
  
 
 
Assessment on Follow up studies   
40 patients were followed up for a mean period of 59 months. Of these two patients 
expired during the follow up period. One patient died due to septic shock secondary 
to community acquired pneumonia within the first year after initiating cART and 
another patient died following an acute abdomen and salmonella septicemia in the 
third year of follow up. No patient in the study group expired due to any neurological 
complication.  
During the follow up period, the mean CD4 count increased from 165 (± 77.17) cells / 
µL to 686(± 287) cells / µL.  The mean weight of the patients increased from 
54.5(±10.3) to 57.8(±10.2) kg.  Thirty nine patients(97.5%) had serially increasing 
CD4 counts and only three patients(7.5%) had a CD4count less than 200 cells / µL 
at the end of the study period.  The three patients with a CD4 count less than 200 
cells / µL had documented poor adherence.  Twenty three patients (57.5%) had an 
increase in the weight of at least one kilogram and 4 patients had shown a decrease 
in the weight. However this did not correlate with the CD4 count.  
 
Adherence
 
:  36 patients had 100 % adherence at all follow up visits. Three patients 
had 95% and one patient 80% adherence respectively. A persistently low CD4 count 
of less than 200 correlated positively with poor adherence. 
 
  
 
 
Change in ART regimen  
During the follow up period 22 patients (55%) had a change in ART regimen and 3 
patients (7.5%) required  a second change in the cART regimen.  The reason for 
change was drug toxicity in 17 patients (42.5%).  The reason for change within 3 
months was associated with a Nevirapine based regimen and the use of Stavudine 
was associated with a change in cART regimen after one year ( p=0.007) . As per 
the new NACO policy Stavudine has been phased out of the new cART regimens 
and all patients with long term stavudine use. have been switched to Zidovudine or 
Tenofovir.  
 
 Table 10: Change in ART regimen during follow up 
 
 
 Change in cART Regimen  
 
Frequency Percent 
  
  
  
cART changed within 3 months 
8 20.0% 
cART changed after one year 
14 35.0% 
No change in cART regimen 
18 45.0% 
Total 
40 100.0% 
 
 
 
  
 
 
 
 
 
 
 
 
Table 11:  Reason for change in the cART regimen during follow up 
 
 
 Reason For Change in cART during follow up  
 
Frequency Percent 
  
  
  
  
  
  
no change in regimen 
18 45.0% 
Lactic acidosis 
1 2.5% 
Severe anaemia 
1 2.5% 
Nevirpine Induced Drug rash 
4 10.0% 
Completed ATT 
5 12.5% 
Long term use of Stavudine 
11 27.5% 
Total 
40 100.0% 
 
 
Figure 5:  New cART regimen during follow up 
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 Neurological assessment on follow up  
 All forty patients had serial neurological examinations on the following visits.  
Two patients expired during the follow up period. One patient died due to septic 
shock secondary to community acquired pneumonia within the first year after 
initiating cART and another patient died following an acute abdomen and salmonella 
septicemia in the third year of follow up. Thirty eight patients were followed up till the 
end of the study period in March 2013. All followed up patients had repeat 
electrophysiological studies at the end of the study period. Only twenty eight patients 
had SSR testing. All patients were scored with the Total Neuropathy Score(TNS). 
Since QST was not performed, the QST component of TNS was excluded.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptomatic HIV neuropathy was seen in 3 (5.4%) patients and, asymptomatic HIV 
neuropathy was seen in 13 (23.2%) patients. 40 patients who were negative for 
neuropathy were followed up for a mean period of 59 months. At the end of the study 
period a total of 8 (20%) patients developed DSP and 3 (7.5%) patients developed 
symptomatic DSP.  
OUTCOME 
 
FIGURE 6 : FLOW CHART SHOWING STUDY OUTCOMES  
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Neuropathy = 8 
 
NORMAL 
= 40 
Patients 
enrolled at the 
time of initiating 
ART = 56 
Expired = 2  
NEUROPATHY 
PRESENT 
 
 
SYMPTOMATIC= 3 
ASYMPTOMATIC= 13 
 
Normal = 30 
Types of Neuropathy  
Motor sensory axonal 
neuropathy  7 
Sensory neuropathy 2 
Polyradiculoneuropathy 2 
Mononeuritis multiplex 2 
 
Table 12: Clinical and Electrophysiological parameters in patients with DSP  
 
R = Reduced, N= Normal, Y = Yes, N= No  
 
Symptomatic DSP while on cART 
Three patients were detected to have a symptomatic DSP during the study period. 
The patients complained of burning type of paresthesias over the feet. All three 
patients had impaired vibration sense over the great toes. Two of the patients had 
graded symmetrical loss of pain sensation below the ankle. The Deep tendon 
reflexes were absent in one patient and was reduced in the other two. None of the 
patients had any motor weakness and Romberg’s sign was negative in all three. Two 
of the patients were on a Stavudine based regimen and hence the cART regimen 
was changed. Two patients with symptomatic DSP had abnormal SNAPs in the 
Sural or superficial peroneal nerves as well as an abnormal SSR. One patient with 
DSP had an absent SSR as the only electrophysiological abnormality.  
 
 
Patient profile Clinical Examination Electrophysiological Testing Diagnosis 
Patient symptoms Loss of pain 
Vibratio
n 
Reflex
es 
CMAP
s F Wave 
Sural 
SNAP 
S.pero
neal 
SNAP 
SSR  TNS SDSP DSP 
1 present 
 
present 
 
Absent _ 
 
 
R 
prolong
ed 
 
R 
 
 
R Absent 17 Y Y 
2 Absent Absent present ++ N Normal R  N present 6 N Y 
3 present  Absent Absent + 
 
N Normal 
R 
 
R 
 Absent 14 Y Y 
4 Absent Absent present ++  N 
prolong
ed 
R 
 
N 
 present 4 N Y 
5 present present Absent + N Normal N N Absent 8 Y Y 
6 Absent Absent present ++ N Normal N R present 4 N Y 
7 Absent Absent present ++ N Normal R R present 6 N Y 
8 Absent Absent present ++ N Normal R R present 6 N Y 
Total 3 2 2 3 1 2 6 5 3  3 8 
 Asymptomatic DSP while on cART  
 
Five patients were detected to have a DSP based on electrophysiological testing 
alone. All of these patients had a normal neurological examination. Absent or 
reduced SNAPs in the sural or peroneal nerves was the only electrophysiological 
abnormality detected. 
 
Electrophysiological characteristics of DSP while on cART  
 Of the eight patients with DSP the reduction of Sural or superficial peroneal SNAPs 
was the only consistent abnormality detected. Six patients had abnormal sural 
SNAPs and six patients had abnormal superficial peroneal SNAPS. Sural SNAPs 
were more involved than superficial peroneal SNAPs in three patients. One patient 
had absent SSR as the only electrophysiological abnormality.  Only in one patient    
the superficial peroneal SNAP was more involved than the Sural SNAPs.  In three 
patients (37.5%) mild asymmetry was noted on electrophysiology but there was no 
correlation with clinical symptoms.  Absent SNAPs was associated with symptomatic 
DSP(p=0.018). One patient with symptomatic DSP had mild reduction in the 
peroneal and tibial CMAPs. However there was no associated motor weakness.   
One of the patients with asymptomatic DSP had a prolongation of bilateral median, 
peroneal an tibial nerve distal latencies with mild reduction in the conduction 
velocities.  There were no motor conduction blocks. There was prolongation of F –
waves in the lower limb nerves. This patient did not fulfil the  diagnostic criteria for 
CIDP by Cornblath et al (108).  
 
  
Table 13: Electrophysiological characteristics of DSP while on cART  
 
  N Minimum 
Maximu
m Mean Std. Deviation 
Right superficial peroneal SNAP 8 .00 23.00 13.6250 8.55 
Left superficial peroneal SNAP 8 4.00 21.00 10.7500 6.09 
Right Sural SNAP 8 .00 28.00 14.3750 9.04 
Left Sural SNAP 8 .00 25.00 11.6250 9.27 
 
 
 
Table 14: Abnormal Electrophysiological findings in patients developing DSP 
while on first line cART 
 
Abnormal Electrophysiological findings in patients with DSP 
while on cART 
 
Frequency Percent 
  
  
  
Abnormal SNAPs 7 100% 
Abnormal Sural SNAPs 6 75% 
Abnormal Superficial peroneal SNAP 5 62.5% 
Asymmetrical involvement 3 37.5% 
Sural  andSuperficial peroneal equally involved 3 37.5% 
Sural SNAP more involved 3 37.5% 
Superfical peroneal SNAP more involved 1 12.5% 
Absent SNAPs 3 37.5% 
Abnormal F waves 2  25% 
Reduction in CMAPs 1  12.5%  
Absent SSR 3 37.5% 
Multiple Lower limb nerve involvement 1  12.5% 
 
 
 TOTAL NEUROPATHY SCORE 
All patients were scored on the Total Neuropathy Score. Eight patients were 
detected to have abnormal scores. Since QST was not performed on our patients the 
QST component of the TNS score was excluded. The patients with symptomatic 
DSP had the highest TNS score (Table 14). A high TNS score was significantly 
associated with increasing age and neuropathic symptoms (p=0.006). The 
symptomatic patients had a score of 3 on the VAS pain score.  
 
 
 
Table 15: TOTAL NEUROPATHY SCORE  
 
 
Total neuropathy Score N Minimum Maximum Mean Std. Deviation 
TNS - Sensory symptoms 8 0 3 0.625 1.06 
TNS  - Motor symptoms 8 0 0 0 0 
TNS  - Autonomic symptoms 8 0 0 0 0 
TNS -  Pin sensibility 8 0 2 0.5 0.76 
TNS  - Vibration sensibility 8 0 2 0.5 0.76 
TNS  - Strength 8 0 0 0 0 
TNS - Tendon reflexes 8 0 2 0.875 0.64 
TNS -  QST 0     
TNS  - sural amplitude 8 2 5 3.125 1.36 
TNS -  peroneal amplitude 8 2 5 3.375 0.92 
Total Neuropathy Score 8 4 17 9.0 4.87 
 
 
 
 
 
  
 
SYMPATHETIC SKIN RESPONE  
 
SSR was done in twenty eight patients (70%). All patients with a diagnosis of  DSP 
had SSR done.  SSR was tested in both upper and  lower limbs. Of the twenty eight 
patients tested twenty five were  normal and SSR was absent in three patients with 
DSP.  Two patients (67%) with symptomatic DSP had abnormal SNAPs with an 
absent SSR and one patient with symptomatic DSP (20%) an absent SSR as the 
only electrophysiological abnormality. Absent SSR was significantly associated with 
a high TNS score and the development of  DSP(p=0.017).  Use of a Stavudine 
based regimen was associated with an absent SSR(p=0.05). There was no 
differential involvement of the lower limbs as compared with the upper limbs. 
 
 
 
Risk Factors for DSP   
 
On univariate analysis the development of DSP was associated with an age greater 
than 40 (p=0.018) and a male sex(p=0.052). There was no association between the 
duration of disease, WHO stage, initial CD4 count or baseline BMI. However the 
failure to demonstrate a weight gain and a loss of weight was associated with the 
development of DSP(p=0.05). There was no association between the cART regimen 
and the development of DSP. Stavudine use was not significantly associated with 
the development of DSP. However stavudine use was associated with an absent 
SSR(p=0.05).  A CD4 cell count of less than 500 was associated with the 
development of DSP( p=0.04). There was no association between the use of an INH 
based ATT regimen and development of DSP. There was no association between 
the duration of disease and DSP.  Since the number of outcomes was small 
multivariate analysis was not performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 This study reveals a relatively low prevalence of DSP, in both the cross sectional 
cART naïve South Indian adults with advanced HIV infection as well the prospective 
cohort of South Indian adults followed up while on cART.  
Discussion 
                   At the time of enrollment, 23.2% of the ART naïve patients being 
screened had a HIV associated DSP, but only 5.4% had symptomatic HIV 
associated DSP. The prevalence of  HIV neuropathy by this study is much lower as 
compared to the study by Cherry et al, which described the prevalence of HIV 
neuropathy  as 55%(7).  In a study from the United States of America (USA) Shifitto 
et al found that 20 % of their patients had Asymptomatic HIV neuropathy  and 35 % 
had symptomatic HIV neuropathy (59).  Our finding of the prevalence of 
asymptomatic HIV neuropathy is similar to that of western data. However the 
prevalence of symptomatic DSP is much lower compared to western studies. Other 
studies from India have found similar prevalence of symptomatic HIV neuropathy. 
Wadia et al reported a prevalence of  5.6% for HIV neuropathy detected by clinical 
examination(16).  In a study from CMC Vellore on PLHA receiving first line cART, Ajit 
Sivadasan et al,  identified symptomatic HIV neuropathy  warranting change of ART 
regimen in 5.2%(109).  Studies from Africa and Asia- pacific regions reveal a similar 
trend as seen in India. Beadles et al, in a study from Malawi reported a prevalence of 
13 % and Wright et al reported a prevalence of 19.7% from the Asia pacific 
counties.(110, 111). In Australia however, despite its geographical  proximity  to the 
Asia-pacific, Smyth et al report a high, 42 % prevalence of HIV neuropathy (112).  
The differences we see in the prevalence of symptomatic HIV neuropathy is possibly 
due to the differences in the study setting, differing age distribution , co morbid 
illnesses, substance abuse , concurrent use of D4T based ART regimen and 
probably ethnicity(63). There is increasing evidence that  ethnicity could be a 
possible  risk factor for the development of HIV neuropathy(63, 64, 111). This could 
possibly explain a relatively low prevalence of HIV neuropathy seen in countries with 
predominantly non-Caucasian population such India, Africa and the Asia-pacific 
region. In countries with a significant Caucasian population the incidence is relatively 
high such as the United States and Australia (7, 8, 112).  Robinson-Papp et al 
studied differences in the prevalence of HIV neuropathy amongst non-Hispanic 
white, Hispanic, and African American PLHA and detected Hispanics to be more 
susceptible along with higher pain scores(64). This suggests that there are ethnic 
disparities in the clinical manifestations of HIV-related neuropathies including pain 
and the susceptibility to Neurotoxic cART. Mitochondrial DNA haplogroup 
polymorphisms  and proinflammatory cytokine genes  have been identified as the 
possible genetic basis for these ethnic differences in the prevalence of HIV 
neuropathy and nucleoside neuropathy (113-115).  The carriage of a cytokine TNF 
alpha polymorphism such as TNFA-1031*2 was detected to have a  higher risk for 
the development of  nucleoside neuropathy. Also the carriage of IL12B (3' UTR)*2 
had protective role in preventing Nucleoside neuropathy(114).  Polymorphisms of 
mitochondrial haplogroup T namely T:MTND2*LHON4917G that was associated with 
the development of nucleoside neuropathy(115). Variations of the hemochromatosis 
gene has also  been studied, and the genotype HFE C282Y was found to have a 
lower risk for developing nucleoside neuropathy (114, 116).                                            
                        All the patients in our study were from an outpatient setting, and had 
a lower mean age as compared to western studies. Co-morbidities such as diabetes 
and substance abuse including alcohol were excluded. At the baseline all the 
patients were ART naïve. These factors could be the possible reasons for reporting a 
lower rate of HIV neuropathy in our study.  Also this difference could be contributed  
by the differences in the assessment methods. In our study only conventional nerve 
conduction studies (NCS) were performed on all patients. Sympathetic skin response 
was done for a majority of patients. QST was not done due to technical difficulties. 
Though epidermal nerve fiber density(ENFD) is a proven tool to assess HIV related 
DSP it was not included in our assessment due to its non availability in our centre 
(65, 117). Hence compared to studies that used QST and ENFD for detecting HIV 
neuropathy, our study using only NCS, could have differing results in view of 
different assessment methods. 
 
               At the time of initial screening and enrollment, patients detected to have a 
neuropathy were found to an axonal length dependent neuropathy. Of the three 
patients with symptomatic DSP prior to initiation of cART all had a motor sensory 
axonal neuropathy. The presence of symptoms did not correlate with age, duration of 
disease, CD4 counts, WHO stage and severity of axonopathy. Of the thirteen 
patients with asymptomatic HIV neuropathy, seven patients had both motor and 
sensory involvement, while two had only sensory involvement. This pattern of 
involvement is similar to that described in literature(118-121). On testing of motor 
parameters, the peroneal nerve was the commonest nerve affected, followed by the 
median and ulnar nerves. In the Upper limbs there was no difference between the 
involvement of the median and ulnar nerves. However in the lower limbs the 
peroneal nerves were more involved.  
               F waves are known to be prolonged in patients with HIV infection(118). In 
this study too, patients with HIV neuropathy had prolonged F waves. The lower limbs 
were more affected as described in other NCS studies(118). Abnormalities of F-
waves have been identified as early features of DSP such as diabetic 
polyneuropathy(122) The measurement of F wave duration( F-dur) is useful in 
identifying early diabetic polyneuropathies and may be used in the setting of early 
HIV neuropathy(122).Of the upper limb nerves studied both the median and ulnar 
nerves were equally involved except for two patients who had a mononeuritis 
multiplex pattern of involvement. The nerves involved were median, ulnar and 
peroneal nerves.  Mononeuritis multiplex in HIV infection is seen commonly in 
disseminated CMV disease and less commonly Hansen’s disease, Vasculitis, 
cryoglobulins, and Hepatitis B infection(123-127). Though both our patients did not 
have Hansen’s disease, one patient was found to have co-infection with hepatitis B 
virus. There was no evidence of CMV retinitis or colitis in both patients. The patients 
however were clinically asymptomatic and showed no neurological progression. 
Hence further etiological work up was not done. Two patients with out evidence of 
HIV neuropathy had asymptomatic carpal tunnel syndrome, however our patients 
were not on a protease inhibitor. One patient was detected to be a diabetic on diet. 
Carpal tunnel syndrome has been described in patients with HIV infection and it is 
postulated that there could be an association with concomitant use of protease 
inhibitors (128-130).  
                On sensory testing, the lower limbs were more affected than the upper 
limbs; as suggested by the sural nerves being more affected than the median and 
ulnar nerves; both in terms of numbers affected as well as severity. The severity of 
the drop in SNAPs did not correlate with the presence of symptoms or other 
identified risk factors.      In our study we found that on univariate analysis Low CD4 
cell count, advancing age, duration of disease and clinical stage of disease were 
identified as risk factors. However on multivariate analysis the association with low 
CD4 cell count was not significant when it was adjusted for other risk factors                               
In pre–HAART era studies, the risk factors for HIV neuropathy were advancing age, 
severity of immunosuppression, low CD4 cell counts and increased HIV plasma viral 
loads(62, 131). However recent studies have shown no such correlations with CD4  
cell counts and plasma viral load(63). Advancing  age and substance abuse 
disorders were detected as risk factors(63). Concurrent use of ATT (isoniazid based) 
was postulated to be a risk factor, however there was no association detected in our 
study. Patients with alcohol abuse were excluded, there were no patients with 
substance abuse and Plasma viral load was not done routinely, hence these factors 
could not be explored.  
 
                 All enrolled patients were initiated on first line HAART as per NACO 
guidelines. A Stavudine based regimen was used in 62.5% of the patients and 
Nevirapine was used as the NNRTI in 82.5% of the patients. During the median 
follow up period of 59 months 55% had a change in ART regimen of which 42.4% 
was attributed to drug toxicity. The incidence of regimen change as per our study is 
much higher when compared to other similar studies in India. Kumarasamy et al 
found  that 20% of their patients on first line generic ART had a regimen change(17).  
In a study from CMC vellore, Ajith Sivadasan et al found that during a median follow 
up period of 48 weeks 27 % of the patients receiving first line generic ART 
developed a severe adverse drug reaction(ADR) requiring a change in ART regimen. 
This  higher proportion of regimen change could be attributed to the longer follow up 
period  of 59 months in our study as well the policy of switching  over from Stavudine 
to Zidovudine or Tenofovir in patients with long term use of Stavudine.  
                                 During the follow up period of 59 months eight patients 20% 
were detected to have a DSP of these three patients (7.5%) were detected to have 
symptomatic DSP.  The period prevalence of symptomatic DSP while on cART as 
measured by our study is similar to the studies reported in literature.  In India in a 
cohort of 3154 South Indian PLHA on generic cART, of whom 54.8% was on a 
stavudine based regimen, Kumarasamy et al found the prevalence of  peripheral 
neuropathy was 9 %(132). The use of stavudine was identified as a risk factor for 
peripheral neuropathy. In a study by van Griensven in Rwanda the prevalence of 
clinically detected, symptomatic  cART associated neuropathy was 8%   (133).  
Though the methods of assessing DSP in various studies are different,  the 
prevalence of symptomatic DSP while on cART as estimated in our study is 
consistent with that published in literature.  However the total period prevalence of 
DSP associated with cART of 20 % over a mean period of 59 months is much lower 
than that reported in literature.  This could be contributed partly by the timely 
switching over of Stavudine to Zidovudine or Tenofovir, in patients who have been 
on long term Stavudine in accordance with the current WHO and NACO guidelines. 
Since epidermal nerve fibre density which is more a sensitive tool than 
electrophysiological testing that was used in our study for the diagnosis of DSP, a 
low estimate in our study could be contributed by this. Also this low prevalence of 
DSP in our study could be attributed to the protective effect of ethnicity; as a low 
prevalence of both symptomatic and asymptomatic DSP has been reported in the 
non-Caucasian populations (111).  On electrophysiological testing the reduction of 
SNAPs in the Sural and superficial peroneal nerves was the most consistent 
findings. One of the patients had a prolongation of the median, peroneal and tibial 
nerve distal latencies, prolongation of F –waves in the lower limbs  and mild 
reduction in the conduction velocities. However she did not fulfil the Cornblath 
criteria for CIDP. One patient with symptomatic DSP had mild reduction in the 
peroneal CMAPs.  Of the sensory nerve abnormalities, there was involvement of 
both sural and superficial peroneal nerves. Three patients with DSP  had equal 
involvement  of both sural and Superfical peroneal nerves and three patients had 
more involvement of the sural nerves. Only one patient had more involvement of  the 
superficial peroneal SNAPs. This is consistent with the increase in yield in utilising 
the  superficial peroneal SNAPs in the diagnosis of DSP(134). Total neuropathy 
score(TNS) is a validated score in the assessment of DSP. TNS scores were 
abnormal in all our patients with DSP(135).   Since QST was not performed on our 
patients the QST component of the TNS score was excluded.  A high TNS score was 
predictive of symptomatic DSP as well as an absent SSR.  It is postulated that HIV 
neuropathy preferentially affects myelinated fibres and anti-retroviral therapy affects 
unmyelinated fibers(136).  Sympathetic skin response(SSR)  is a good tool to assess 
the function of small unmyelinated fibers and SSR is widely used as an adjunctive 
electrophysiological test for the assessment of peripheral neuropathy with 
involvement of small fibers(137).  The use of SSR was comparable to that of QST 
and other techniques such as   nociceptive evoked potentials  and current perception 
threshold(CPT)(138, 139). SSR has been used in the diagnosis of nucleoside 
neuropathy(140). In our study of the twenty eight patients who underwent SSR, three 
of the patients with DSP had an absent SSR. Of these, two patients had 
symptomatic DSP. There was no differential involvement of SSR on comparing the   
the upper and lower limbs. All three patients had an absent SSR in both upper limbs 
and lower limbs. Though SSR in the lower limbs is more commonly absent in axonal 
neuropathies such and HIV and diabetes, a concomitantly absent SSR in both upper 
and lower limbs is also a common finding, as seen in our study(141, 142). The 
absent SSR was associated significantly with symptomatic DSP. Also the absent 
SSR was associated with the use of a Stavudine based regimen. This is consistent 
with the hypothesis that anti-retroviral therapy affects unmyelinated fibres as 
assessed by the SSR(140).  The risk factors for the development of DSP while on 
cART detected in our study were, age greater than 40, a persistently low CD4 count 
of less than 500, and weight loss while on cART.  . Though there was no association 
of DSP while on cART with use of a Stavudine based regimen, and absent SSR was 
associated with Stavudine use. Though the use of INH as part of ATT regimen has 
been associated with the development of DSP; there was no association that was 
demonstrated.   
  
 The major limitations in our study include  
1. Only conventional NCS (with a diagnostic yield of only 60%) was used for the 
diagnosis of asymptomatic HIV neuropathy; QST and ENFD were not done due 
to technical difficulties. 
2. Baseline plasma viral load and follow up CD4 cell counts were not available for 
all patients; hence it could not be used for analysis. 
3. SSR was not done at baseline and could not be done for all follow up patients  
4. Since QST was not performed the QST component of the TNS could not be 
assessed  
5. Repeat NCS was not serially available for all patients during follow up visits; 
hence the incidence of asymptomatic DSP could not be studied. 
6. Since the number of patients with DSP was small multivariate analysis could not 
be performed 
 
Conclusion 
1. Of the fifty six cART naive HIV positive patients screened 23.2% of the ART 
were detected to have DSP. 
 
2. The prevalence of symptomatic DSP amongst cART naïve patients with HIV 
was detected to be 5.4%. 
 
3. Low baseline CD4 cell count, advancing age, increasing duration of disease 
and advanced clinical stage of disease were identified as risk factors for DSP 
amongst the cART naive patients. 
 
4. During the follow up of forty patients on first line generic cART  over a  period 
of 59 months eight patients 20%  were detected  to have a DSP  
 
 
5. The prevalence of symptomatic DSP while on first line cART was found to be 
7.5%. 
  
6. The risk factors for the development of DSP while on cART  were an age 
greater than 40, a persistently low CD4 count of less than 500  and weight 
loss while on cART.  Absent SSR was associated with symptomatic DSP as 
well exposure to a Stavudine based cART regimen.  
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ANNEXURES  
DATA COLLECTION PROFORMA 
            
           HIV NEUROPATHY 
History                                                                 Date of diagnosis: 
 
 
 
 
 
 
 
 
 
 
CD 4 count Date viral load Date  
 
    
    
    
    
 
 
 
 
 
Co-morbidities : 
Hypertension   Y / N   Diabetes     Y / N 
Smoking   Y / N   Hypercholesterolaemia Y / N 
IHD    Y / N   Alcohol     Y / N 
PVD    Y / N   Obesity    Y / N 
Chronic diarrhoea      Y / N                                  Organo phos exp           Y / N 
Renal failure     Y / N   Vegetarian                     Y/ N 
Native medication Y / N                                  Other toxins        Y / N 
   
 
            
 
 
 
 
 
Name: 
 
Hospital Number: 
 
DOB:  Age: 
 
M/F     
Address: 
 
Telephone/E-mail: 
 
Seen by: 
 
Date:   Time: 
 
Serial number  
 
   
Coding for Sensory Symptoms    
Sensory  
Parasthesia  
        1 
.Symptoms limited to 
fingers or toes 
 
 
       2  
.Symptoms extend to 
ankle or wrist 
    3.  
Symptoms extend to 
knee or elbow 
     4.  
Symptoms above knees 
or elbows, or 
functionally disabling 
Sensory loss          1 
Symptoms limited to 
fingers or toes 
        2 
Symptoms extend to 
ankle or wrist 
    3 
Symptoms extend to 
knee or elbow 
       4 
Symptoms above knees 
or elbows, or 
functionally disabling 
pain          1 
.Symptoms limited to 
fingers or toes 
 
 
       2  
.Symptoms extend to 
ankle or wrist 
    3.  
Symptoms extend to 
knee or elbow 
     4.  
Symptoms above knees 
or elbows, or 
functionally disabling 
Type of pain          1  
Burning type  
       2 
Pricking type 
  
Motor         1 
Difficulty in hand grip  
        2 
Difficulty in combing, 
reaching up to shelf 
        3 
Difficulty in turning in 
bed  
   4  
Bulbar symptoms  
        5 
Difficulty in gripping 
foot wear, footwear 
slipping off  with 
knowledge 
     6 
Twisting of ankle, 
buckling of knee  
      7 
Difficulty in getting up 
from squat  
     8 
Complete paralysis 
Bladder  
 
     0 
absent  
        1  
 present  
  
            
           
 Symptoms                                               Duration of symptoms: 
 Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6 
Paresthesias        
Pain        
Pain type        
Sensory loss       
Motor        
Bladder        
 
            
    
          
 
 
  
 
Opportunistic infection in the past  
 
Pulmonary tuberculosis                                   Time of dx :                     Duration of Rx:  
Extapulmonary tuberculous                            Time of dx :                     Duration of Rx:              site: 
PCP pneumonia                                
CMV retinitis                                     
Others                                                                Details :  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
            
            
            
            
    
 
General Examination:     
Temp:   Pulse:            reg/irreg   
Blood pressure:  lying/   sitting/      standing/Height:                       Weight:                         BMI :  
 
CVS   Abdo:   Chest:   
                                                                                                                          0 = Normal ,  I =  Abnormal  
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Gen exam       
Weight       
CVS       
RS       
ABDO       
 
Neurological examination: 
The Mini-Mental Status Examination (MMSE)  Points 
Orientation 
Name: season/date/day/month/year  
Name: hospital/floor/town/state/country 
  
5 (1 for each name) 
5 (1 for each name) 
Registration 
Identify three objects by name and ask patient to repeat 
  
3 (1 for each object) 
Attention and calculation 
Serial 7s; subtract from 100 (e.g., 93-86-79-72-65) 
  
5 (1 for each subtraction) 
Recall 
Recall the three objects presented earlier 
  
3 (1 for each object) 
Language 
Name pencil and watch  
Repeat ‘‘No ifs, ands, or buts’’  
Follow a 3-step command (e.g., ‘‘Take this paper, fold it in half, and 
place it on the table’’) 
Write ‘‘close your eyes’’ and ask patient to obey written command 
Ask patient to write a sentence  
Ask patient to copy a design (e.g., intersecting pentagons) 
  
2 (1 for each object) 
1 
3 (1 for each command) 
  
1 
  
1 
1 
TOTAL  
 
MMSE  Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
OrientTime       
Orien Place       
Registration        
Attention       
Recall       
Naming       
Repetiton        
Commands       
Writ comnd       
Sentence        
Design        
TOTAL        
 
 
 Cranial Nerves                                                                              0 = Normal , 1 =Abnormal  
Cranial nerves Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Olfactory        
Vision        
Fundus        
Eye movmnt       
Trigeminal        
Facial        
Vest Coclr        
 Palate        
Sternomastoid        
Tongue        
 
                Motor Examination  
 
       Bulk and Tone                                 
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Wasting        
Tone        
                                                                                                           0 = Normal,  1 = Decreased , 3 Increased  
 
        Power                                                                                     
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Power  R L R L R L R L R L R L 
Neck flx             
Neck ext             
Trunk              
Should Abd             
Should Add              
Elbow Flx             
Elbow Ext              
Wrist Flx              
Wrist Ext              
Hip Flx              
Hip Ext              
Knee Flx              
Knee Ext              
Dorsiflx              
Plantar             
                                                                                                                                                                         MRC Scale                                                                       
0 No contraction                                                                                                                                                       
                                                                                              1 Flicker or trace of contraction 
                                                                                      2 Active Movement with gravity eliminated                                                                           
3 Active Movement Against gravity 
                                                                                                         4 Active Movement Against gravity & resistance 
                                                                                                            5Normal power 
 
 
 
 
 
 
 
Reflexes  
 
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Reflexes  R L R L R L R L R L R L 
Biceps              
Brachiorad              
Triceps              
Knee              
Ankle              
Sup abd             
Plant r             
 
                                                                                                                                                                                Reflex Grading 
 0 Absent 
 +/-  Present with reinforcement 
+ Decreased 
 ++ Normal 
 +++ Increased 
 C With clonus 
 
 
 
 
 
 
        
Sensory examination  
        
  Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
 Sensory  R L R L R L R L R L R L 
Up.Limb  Fine touch              
 Vibration              
 Temperature             
 Joint pos              
 Monofilamnt             
Lo.Limb Fine touch              
 Vibration              
 Temperature             
 Joint pos              
 Monofilamnt             
                                                              0 = Normal , 1 = Abnormal    ( quantify sensory loss in %  25/ 50 / 75/ 100) 
 
 
 shade areas with sensory loss  
 
 
Cerebellar and Gait  
  
 Visit 1 Visit 2 Visit 3  Visit 4  Visit 5  Visit6  
Cerebel       
Romber       
Gait        
Nk stif       
                                                                         0 = Normal, 1 = Abnormal                                                    
 Electrophysiology  
 Visit 1 Visit 2 Visit 3  Visit 4  Visit 5  Visit6  
NCV        
EMG        
QST        
END        
                                                                                                               0 = Normal, 1 = Abnormal 
        
Type of Neuropathy :  Nil / DSP/ AIDP/CIDP  
 
 
 
 
 
 
 
 
 
 
INFORMED CONSENT FORM 
Informed Consent form to participate in a clinical trial 
Study Title:  HIV Neuropathy – incidence and risk factors 
Serial Number: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please initial box  
(Subject) 
 
(i) I confirm that I have read/ have been explained to in my own language and have fully understood the 
information sheet dated _________ for the above study and have had the opportunity to ask any questions that I 
had. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected. 
[ ] 
 However, I understand that my identity will not be revealed in any information released to third parties or 
published. [ ] 
 (v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______Study Investigator’sName: _________________________   signature of the 
Witness: ___________________________ 
 
 
 
 
 
 
 
 
 
Investigations  
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Hb        
TC       
DC        
Platelets       
Lipids        
AC       
PC        
Creat       
Vitamin B 12        
Lactate        
                                                                                                                   ANTIRETROVIRAL THERAPY :   
ART Regimen :               AZT / 3TC / NVP    □                Details  
                                              AZT / 3TC / EFV    □ 
                                               D4T/ 3TC / NVP    □ 
                                   D4T/ 3TC / EFV     □ 
                                              Others                      □ 
        Adherence                      
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Adherence        
Pill count       
         Adverse events  
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Neurological #       
Skin rash        
Gastro int        
Bonemarrow       
Metabolic       
Others        
                                                                                                                                                        # -other than DSP              0 = Normal , 1 = Present   
Change in  ART regimen Reason for change Date 
   
   
   
   
               
TOTAL NEUROPATHY SCORE 
 
Parameter 
Score 
0 1 2 3 4 
QST = quantitative sensory test; ULN = upper limit of normal; LLN = lower 
limit of normal. 
Sensory 
symptoms 
None Symptoms 
limited to 
fingers or 
toes 
Symptoms 
extend to 
ankle or 
wrist 
Symptoms 
extend to knee 
or elbow 
Symptoms 
above knees 
or elbows, 
or 
functionall
y disabling 
Motor 
symptoms 
None Slight 
difficulty 
Moderate 
difficulty 
Require 
help/assistanc
e 
Paralysis 
Autonomic 
symptoms, 
n 
0 1 2 3 4 or 5 
Pin 
sensibilit
y 
Normal Reduced in 
fingers/toe
s 
Reduced up 
to 
wrist/ankl
e 
Reduced up to 
elbow/knee 
Reduced to 
above 
elbow/knee 
Vibration 
sensibilit
y 
Normal Reduced in 
fingers/toe
s 
Reduced up 
to 
wrist/ankl
e 
Reduced up to 
elbow/knee 
Reduced to 
above 
elbow/knee 
Strength Normal Mild 
weakness 
Moderate 
weakness 
Severe 
weakness 
Paralysis 
Tendon 
reflexes 
Normal Ankle 
reflex 
reduced 
Ankle 
reflex 
absent 
Ankle reflex 
absent, others 
reduced 
All 
reflexes 
absent 
Vibration 
sensation 
(QST 
vibration) 
Normal to 
125% ULN 
126 to 150% 
ULN 
151 to 
200% ULN 
201 to 300% 
ULN 
>300% ULN 
Sural 
amplitude 
Normal/reduce
d to <5% LLN 
76 to 95% 
of LLN 
51 to 75% 
of LLN 
26 to 50% of 
LLN 
0 to 25% of 
LLN 
Peroneal 
amplitude 
Normal/reduce
d to <5% LLN 
76 to 95% 
of LLN 
51 to 75% 
of LLN 
26 to 50% of 
LLN 
0 to 25% of 
LLN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY TO MASTER CHART 
 
 
 Variable Name Value Label 
1 Sex 1 Male  
2 Female 
2 Durattion of HIV infection 0 < 2 years  
1 > 2 years 
3 Marital Status 0 Single 
1 Married 
4 Occupation 0 House wife 
1 Manual Laborer 
2 Driver 
3 Farmer 
4 Business 
5 Office 
5 Educational Status 0 Illiterate 
1 Primary school 
2 Secondary school 
3 Graduate  
4 Post graduate 
5 Literate  
6 WHO Stage 1 WHO stage I 
2 WHO stage II 
3 WHO stage III 
4 WHO stage IV 
7 Tuberculosis 0 No history of tuberculosis 
1 Sputum positve pulmonary tuberculosis 
2 Sputum negative pulmonary tuberculosis 
3 Disseminated Tuberculosis 
4 Tuberculosis Meningitis 
5 Tuberculous Lymphadenitis 
8 ART 1 AZT/3TC/NVP 
2 AZT/3TC/EFV 
3 D4T/3TC/NVP 
4 D4T/3TC/EFV 
9 HIV neuropathy 0 No evidence of neuropathy 
1 HIV Neuropathy present 
10 Others 0 Absent  
1 Present  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
A B C D E F G H I J K L M N O
SNO ARTnu cARTneurop sympDSP SSR Name HospNo Adress TelNo Age a40 ag Sex DoFv DoDx
48 335 1.00 1.00 1.00 Vijayakumar 398020D Vellore #NULL! 34 0 2 1 28-Jan-2009 27-Jan-2009
30 284 1.00 1.00 1.00 Sarangan 366324D Walajapet 9,994,790,544 41 1 3 1 17-Dec-2008 02-Dec-2008
51 380 1.00 1.00 1.00 Rani 787474D Chittoor 9,490,277,228 37 0 2 1 01-Mar-2009 09-Sep-2005
18 245 1.00 0.00 0.00 Ponnuswamy 347204D Vellore 9,443,430,033 47 1 3 1 12-Nov-2008 20-Mar-2008
11 204 1.00 0.00 0.00 Latha 235949D Gudiyatham #NULL! 42 1 3 2 23-Jul-2008 09-May-2008
56 269 1.00 0.00 0.00 Gowri 356955D Arni #NULL! 35 0 2 2 27-Nov-2008 17-Nov-2008
19 244 1.00 0.00 0.00 Basha.S.M 336087D Chittoor 9,291,600,634 60 1 4 1 19-Oct-2009 29-Jun-2006
47 364 1.00 0.00 0.00 Arumugam 414611D Vellore 9,843,165,563 38 0 2 1 11-Mar-2009 24-Dec-2008
21 246 0.00 0.00 0.00 Venkatesan.G 022667D Vellore 9,448,089,968 35 0 2 1 15-Sep-2008 08-May-2007
55 435 0.00 0.00 0.00 Venkatesan 460033D Vellore 9,677,842,433 43 1 3 1 19-May-2009 12-May-2009
2 182 0.00 0.00 0.00 Usha.K 306318D chitoor 8,573,200,336 40 0 2 2 10-Sep-2008 01-Sep-2008
14 208 0.00 0.00 0.00 Umapathi 314839D Arcot 9,443,430,016 40 1 2 1 15-Oct-2008 17-Sep-2008
27 314 0.00 0.00 0.00 Sudhakar Babu 300780D Vellore #NULL! 29 0 1 1 08-Oct-2008 27-Aug-2008
40 415 0.00 0.00 0.00 Sudeep.P.S 525931C Vellore 9,848,129,302 40 0 2 1 17-Feb-2009 20-Sep-2004
39 414 0.00 0.00 0.00 Subramanyam 666952D Vellore 9,441,524,606 30 0 1 1 10-Apr-2009 12-Jan-2009
15 218 0.00 0.00 0.00 Subathra 303762D Vellore 9,047,881,483 40 0 2 2 08-Oct-2008 17-Sep-2008
54 287 0.00 0.00 0.00 Srinivsan 157396D Vellore #NULL! 41 1 3 1 31-Dec-2008 17-Nov-2008
34 323 0.00 0.00 0.00 Shymala 526912B Vellore #NULL! 35 0 2 2 07-Mar-2008 01-Mar-2008
5 149 0.00 0.00 0.00 Settu.P 368506D Arni #NULL! 38 0 2 1 01-Aug-2000 01-Aug-2008
52 398 0.00 0.00 0.00 Sampath 424067D Polur 4,181,243,321 36 0 2 1 09-Apr-2009 01-Apr-2009
42 337 0.00 0.00 0.00 Padmaja 402616D Chittoor 9,441,080,726 36 0 2 2 11-Feb-2009 03-Feb-2009
17 235 0.00 0.00 0.00 Pachiyappan 326525D Vayaloor 9,600,389,289 49 1 3 1 13-Oct-2008 04-Oct-2008
36 330 0.00 0.00 0.00 Nirubarani 381182D Vellore 9,047,735,620 25 0 1 2 05-Jan-2009 30-Dec-2008
44 360 0.00 0.00 0.00 Nagalingam 351115D Vellore 9,952,853,412 38 0 2 1 05-Jan-2009 05-Jan-2009
32 322 0.00 0.00 0.00 Murthy 375470D Vellore 9,994,049,919 41 1 3 1 24-Dec-2008 17-Dec-2008
53 454 0.00 0.00 0.00 Meena 525400C Vellore 9,952,532,633 36 0 2 2 01-Jun-2009 06-Oct-2004
4 12 0.00 0.00 0.00 Kumudhavalli 180923D polur 9,486,335,461 51 1 4 2 13-Feb-2008 13-Feb-2008
22 285 0.00 0.00 0.00 kumari 369446D Vellore 9,994,790,544 36 0 2 2 17-Dec-2008 03-Dec-2008
29 272 0.00 0.00 #NULL! Kasthuri 350734D Vellore 9,844,425,647 30 0 1 2 01-Dec-2008 20-Nov-2008
25 296 0.00 0.00 #NULL! Kannamma 342421D Krishnagiri 9,952,269,202 45 1 3 2 24-Dec-2008 29-Oct-2008
24 291 0.00 0.00 #NULL! Kalaiselvi 370643D Vellore #NULL! 40 0 2 2 03-Dec-2008 12-Aug-2008
37 332 0.00 0.00 #NULL! Kala 042930D Arcot #NULL! 28 0 1 2 21-Jan-2009 07-Jun-2009
43 339 0.00 0.00 #NULL! Indra Sekar 378417D chittoor 9,949,163,961 35 0 2 1 04-Feb-2009 27-Dec-2008
20 248 0.00 0.00 #NULL! Hari 669811C Vellore 9,952,685,353 39 0 2 1 08-Aug-2008 31-Jul-2005
6 185 0.00 0.00 #NULL! Gandhi 304842D melpootheri, vello 9,976,975,281 27 0 1 1 01-Oct-2008 02-Sep-2008
49 368 0.00 0.00 #NULL! Clarence 383547D Vellore 9,894,636,680 35 0 2 1 16-Jan-2009 07-Jan-2009
45 338 0.00 0.00 #NULL! Chelam.M.V 321286D Nellore #NULL! 36 0 2 1 09-Feb-2008 25-Sep-2008
8 189 0.00 0.00 #NULL! Anitha.A 313020D Vellore 94,162,295,703 20 0 1 2 18-Sep-2008 18-Sep-2008
3 181 0.00 0.00 #NULL! Anbalagan 179321A vellore #NULL! 45 1 3 1 01-Aug-2008 29-Jul-2008
46 336 0.00 0.00 #NULL! Ammu 402824D Vellore #NULL! 28 0 1 2 04-Feb-2009 30-Jan-2009
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
P Q R S T U V W X Y Z AA AB AC AD AE
duration currentstat CD4 cd4100 CD4date CD4f1 Cd4datef1 CD4_2 CD4_3 LastCD4 dateofcd4 sexhis maritalstaIoccpt income education
0.00 0.00 125 0.00 28-Jan-2009 447 #NULL! 354.00 408.00 408.00 27-Sep-2012 1 1 1 1,000 1.00
1.00 0.00 336 0.00 17-Dec-2008 674 #NULL! 649.00 812.00 785.00 27-Jun-2012 1 1 2 5,000 2.00
1.00 0.00 196 0.00 01-Mar-2009 271 #NULL! 351.00 419.00 388.00 22-Nov-2012 1 1 0 1,000 2.00
0.00 0.00 136 0.00 12-Nov-2008 243 28-May-2009 243.00 328.00 290.00 23-Nov-2012 1 1 1 2,000 2.00
0.00 0.00 129 0.00 23-Jul-2008 #NULL! #NULL! #NULL! #NULL! 224.00 #NULL! 1 1 1 1,000 1.00
0.00 0.00 24 1.00 27-Nov-2008 81 #NULL! #NULL! #NULL! 175.00 11-Oct-2012 1 1 1 500 1.00
0.00 0.00 114 0.00 19-Oct-2008 135 05-May-2009 #NULL! #NULL! 520.00 #NULL! 1 1 2 2,000 2.00
0.00 0.00 193 0.00 11-Mar-2009 429 #NULL! 429.00 497.00 497.00 24-Sep-2012 1 1 4 3,000 2.00
1.00 0.00 230 0.00 02-Sep-2008 #NULL! #NULL! #NULL! #NULL! 741.00 #NULL! 1 0 4 5,000 1.00
0.00 0.00 39 1.00 19-May-2009 100 #NULL! 791.00 834.00 1,004.00 19-Sep-2012 1 1 2 3,000 2.00
1.00 2.00 209 0.00 10-Sep-2008 200 #NULL! 200.00 #NULL! 576.00 #NULL! 1 1 1 2,000 1.00
0.00 0.00 189 0.00 15-Oct-2008 359 #NULL! 472.00 526.00 554.00 24-Oct-2012 1 1 2 6,000 2.00
0.00 0.00 100 0.00 08-Oct-2008 #NULL! #NULL! #NULL! #NULL! 680.00 #NULL! 1 1 1 2,000 1.00
1.00 0.00 225 0.00 17-Feb-2009 225 #NULL! 614.00 594.00 530.00 17-Oct-2012 1 1 4 4,000 2.00
0.00 0.00 228 0.00 10-Apr-2009 846 #NULL! 631.00 749.00 680.00 20-Dec-2012 1 1 4 1,500 2.00
0.00 0.00 86 1.00 08-Oct-2008 #NULL! #NULL! #NULL! #NULL! 1,200.00 #NULL! 1 1 1 500 0.00
0.00 0.00 147 0.00 31-Dec-2008 343 #NULL! 356.00 357.00 480.00 27-Jan-2012 1 1 4 10,000 1.00
0.00 0.00 268 0.00 07-Mar-2008 359 28-Jan-2009 #NULL! #NULL! 786.00 #NULL! 1 1 0 500 2.00
0.00 0.00 204 0.00 05-Aug-2008 354 28-May-2009 354.00 409.00 591.00 10-Oct-2012 1 1 1 2,000 1.00
0.00 0.00 100 0.00 09-Apr-2009 100 #NULL! 157.00 184.00 142.00 13-Aug-2012 1 1 0 1,000 2.00
0.00 0.00 233 0.00 11-Feb-2009 232 #NULL! 454.00 303.00 214.00 19-Feb-2012 1 1 1 500 2.00
1.00 0.00 174 0.00 13-Oct-2008 419 #NULL! 436.00 479.00 741.00 14-Dec-2012 1 1 3 2,000 2.00
0.00 0.00 118 0.00 05-Jan-2009 #NULL! #NULL! #NULL! #NULL! 786.00 #NULL! 1 1 0 500 1.00
0.00 0.00 151 0.00 05-Jan-2009 302 #NULL! 281.00 301.00 479.00 23-Sep-2012 1 1 1 1,000 1.00
0.00 0.00 25 1.00 24-Dec-2008 327 #NULL! 544.00 590.00 505.00 08-Jan-2013 1 0 4 4,000 2.00
1.00 0.00 123 0.00 01-Jun-2009 #NULL! #NULL! #NULL! #NULL! 715.00 #NULL! 1 1 0 500 1.00
0.00 0.00 126 0.00 13-Feb-2008 107 #NULL! 370.00 323.00 323.00 29-Aug-2012 1 1 1 1,200 1.00
0.00 0.00 239 0.00 17-Dec-2008 515 #NULL! 679.00 545.00 714.00 27-Jun-2012 1 1 1 3,000 0.00
0.00 0.00 254 0.00 01-Dec-2008 459 #NULL! 845.00 1,072.00 1,031.00 26-Oct-2012 1 1 0 500 0.00
0.00 0.00 174 0.00 24-Dec-2008 602 #NULL! #NULL! 1,083.00 1,282.00 18-May-2012 1 1 0 500 0.00
0.00 0.00 283 0.00 03-Dec-2008 584 #NULL! 1,128.00 1,119.00 1,192.00 23-Aug-2012 1 1 1 500 0.00
0.00 0.00 260 0.00 21-Jan-2009 418 #NULL! 713.00 755.00 672.00 25-Sep-2012 1 1 0 500 2.00
1.00 0.00 268 0.00 04-Feb-2009 685 #NULL! 667.00 690.00 612.00 22-May-2012 1 1 1 500 1.00
0.00 0.00 238 0.00 08-Aug-2008 238 #NULL! 363.00 506.00 665.00 03-Dec-2012 1 1 4 5,000 2.00
0.00 0.00 55 1.00 01-Oct-2008 200 22-Jan-2009 344.00 364.00 458.00 16-Aug-2012 1 0 2 2,000 2.00
0.00 0.00 64 1.00 16-Jan-2009 218 #NULL! 146.00 150.00 170.00 19-Oct-2012 1 1 2 5,000 2.00
0.00 0.00 80 1.00 09-Feb-2008 277 #NULL! 426.00 434.00 376.00 25-Jun-2012 1 1 3 3,000 3.00
0.00 0.00 175 0.00 18-Sep-2008 #NULL! #NULL! 220.00 422.00 448.00 03-Oct-2012 1 0 1 500 2.00
0.00 0.00 189 0.00 01-Aug-2008 304 30-Mar-2009 #NULL! #NULL! 1,072.00 #NULL! 1 1 4 5,000 2.00
0.00 0.00 93 1.00 04-Feb-2009 360 #NULL! 650.00 505.00 647.00 18-Sep-2012 1 1 0 500 2.00
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
AF AG AH AI AJ AK AL AM AN AO AP AQ AR AS AT AU AV AW AX AY AZ BA BB BC BD BE
WHost advhiv Htn Smok IHD PVD ChDiaRenalFNativeMDiabet DyslipdemAlcoh Obesit OP VegetaToxin sensy TubecTB DofATT ATT PCP CMV MISC Height weight
3 1.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0.00 #NULL! 0.00 0 0 0 166 51.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0.00 #NULL! 0.00 0 0 isospora 168 72.0
3 1.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0.00 #NULL! 0.00 0 0 0 165 57.0
3 1.00 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 171 47.4
1 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1.00 28-Jul-2009 1.00 0 0 0 151 42.0
1 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 163 43.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 167 45.3
3 1.00 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 179 67.0
2 0.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 162 64.0
1 0.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 170 62.4
3 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 1.00 10-Sep-2008 1.00 0 0 0 167 77.0
3 1.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 170 72.0
4 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 1.00 01-Sep-2008 1.00 0 0 0 164 45.0
2 0.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 5 1.00 01-Jan-2006 0.00 0 0 0 169 61.0
3 1.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 168 63.0
4 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1.00 17-Sep-2008 1.00 1 0 0 162 50.0
1 0.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 173 63.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 160 41.0
3 1.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 164 56.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 169 60.7
2 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 168 44.0
3 1.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 TPHA 150 55.0
1 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 157 59.0
2 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 170 70.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 160 53.0
1 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 149 46.8
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 1.00 02-Mar-2008 1.00 0 0 0 159 44.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 167 42.8
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 156 37.2
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 isospora 150 45.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 Herpes Z 150 38.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 163 51.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 164 52.0
3 1.00 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 5 1.00 14-Aug-2009 1.00 0 0 0 163 67.0
3 1.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 161 50.0
2 0.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 172 55.0
2 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 1.00 01-Oct-2008 1.00 0 0 0 168 65.0
1 0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 0 0 160 48.0
3 0.00 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 4 1.00 06-Aug-2008 1.00 0 0 0 169 64.0
3 1.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 #NULL! 0.00 0 1 0 164 52.0
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BF
BMI
18.51
25.51
20.94
16.21
18.54
16.18
16.24
20.91
24.39
21.59
27.61
24.91
16.73
21.36
22.32
19.05
21.05
16.02
20.82
21.25
15.59
24.44
23.94
24.22
20.70
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17.40
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15.29
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16.89
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19.29
18.59
23.03
18.75
22.41
19.33
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BG BH BI BJ BK BL BM BN BO BP BQ BR BS BT BU BV BW BX BY BZ CA CB CC CD CE CF CG
W1 W2 W3 W4 W5 W6 CVS RS ABD Bardel B1 MMSE Olfact Vision Eyemovtrig FaciavestcpalatSter wasti Ton Nflx next trunk Shflx Shex
52.0 52.0 52.00 52.00 52.00 52.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
75.3 72.0 74.00 74.00 76.30 77.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
58.9 58.0 57.00 59.00 59.00 61.20 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
49.7 46.0 46.00 48.00 48.00 48.80 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
46.0 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
47.0 43.0 50.00 50.00 53.00 53.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
45.8 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
68.0 67.0 67.00 68.00 68.00 68.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
67.0 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
62.6 55.0 56.00 56.00 5.00 56.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
78.0 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 30 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
72.6 72.0 72.00 72.00 72.00 71.90 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
46.4 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
62.1 61.0 61.00 63.00 63.00 63.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
63.8 63.0 63.00 63.00 63.00 60.70 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
51.0 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
65.2 63.0 63.00 71.00 71.00 73.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
50.0 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
60.2 60.0 60.00 60.00 60.00 60.00 0 0 0 20 20 30 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
62.0 60.7 60.70 61.00 61.00 61.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
47.0 44.0 45.00 45.00 47.00 47.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
58.5 59.0 60.00 61.90 66.00 66.00 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
60.0 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
73.2 72.0 73.00 75.00 75.00 75.00 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
54.5 53.0 55.00 54.50 55.00 55.00 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
47.0 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
45.2 40.0 40.00 44.00 44.00 44.00 0 0 0 20 20 29 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
45.9 44.0 44.00 43.50 44.00 44.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
39.4 37.0 37.20 40.70 40.00 40.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
46.3 48.0 48.00 49.00 49.00 50.20 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
41.0 41.0 41.00 41.00 41.00 41.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
54.0 52.0 53.00 53.00 54.00 53.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
52.2 52.0 52.00 52.00 50.00 50.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
70.6 67.0 67.00 67.00 69.00 69.00 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
55.8 55.0 55.80 59.00 59.00 59.00 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
56.0 55.0 55.00 55.00 62.00 62.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
65.5 65.0 64.00 65.00 65.00 65.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
48.2 46.0 46.00 46.00 47.90 48.00 0 0 0 20 20 26 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
69.7 #NULL! #NULL! #NULL! #NULL! #NULL! 0 0 0 20 20 28 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
52.6 45.0 46.00 46.00 61.00 61.00 0 0 0 20 20 27 0 0 0 0 0 0 0 0 0 0 5 5 0 5 5
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CH CI CJ CK CL CM CN CO CP CQ CR CS CT CU CV CW CX CY CZ DA DB DC DD DE DF DG DH DI
ElbflxElbexwriflxWriexHandHipflx HipeKneeflxKne Dor Plflx AsyBiRef Bire BraRefR BraRefL TrirefR TrirefL KneeJR KneeJL AnkleJR AnkleJLPlantarsPlantaSupabdUlsenFT UlsenVibUlsenPt
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 1 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 1 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 5 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
5 5 5 5 0 5 5 5 5 5 5 0 2 2 2 2 2 2 2 2 2 2 0 0 0 0 0 0
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DK DL DM DN DO DP DQ DR DS DT DU DV DW DX DY
LLsenFT LLsenvib LLsenPT LLsenMon Senpattern cerebellar Romberg Gait Nkstiff ART stavd DoSArt NewART ChangeART DoChaART
0 1 1 1 1 0 0 0 0 3 1.00 12-Feb-2009 2 1.00 24-Nov-2011
0 1 1 0 1 0 0 0 0 3 1.00 25-Dec-2008 1 1.00 06-Jul-2012
0 1 0 1 1 0 0 0 0 1 0.00 02-Apr-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 3 1.00 20-Nov-2008 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 4 1.00 15-Oct-2008 3 1.00 20-Jan-2009
0 0 0 0 0 0 0 0 0 3 1.00 04-Dec-2008 1 1.00 24-Jun-2012
0 0 0 0 0 0 0 0 0 1 0.00 20-Nov-2008 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 1 0.00 19-Mar-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 3 1.00 20-Nov-2008 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 1 0.00 28-May-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 4 1.00 24-Sep-2008 2 1.00 11-Jun-2008
0 0 0 0 0 0 0 0 0 1 0.00 15-Oct-2008 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 1 0.00 22-Jan-2009 3 1.00 25-Feb-2009
0 0 0 0 0 0 0 0 0 1 0.00 07-May-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 1 0.00 07-May-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 4 1.00 30-Oct-2008 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 1 0.00 25-Dec-2008 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 1 0.00 29-Jan-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 3 1.00 20-Aug-2008 1 1.00 27-Jun-2012
0 0 0 0 0 0 0 0 0 3 1.00 23-Apr-2009 1 1.00 24-Apr-2012
0 0 0 0 0 0 0 0 0 3 1.00 12-Feb-2009 1 1.00 02-Mar-2012
0 0 0 0 0 0 0 0 0 3 1.00 14-Nov-2008 1 1.00 #NULL!
0 0 0 0 0 0 0 0 0 3 1.00 05-Feb-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 1 0.00 12-Mar-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 3 1.00 29-Jan-2009 1 1.00 11-Jan-2012
0 0 0 0 0 0 0 0 0 1 0.00 11-Jun-2009 2 1.00 26-Jun-2009
0 0 0 0 0 0 0 0 0 4 1.00 30-Apr-2008 3 1.00 29-Jan-2009
0 0 0 0 0 0 0 0 0 3 1.00 25-Dec-2008 1 1.00 06-Jul-2011
0 0 0 0 0 0 0 0 0 3 1.00 10-Dec-2009 4 1.00 21-Jan-2009
0 0 0 0 0 0 0 0 0 1 0.00 07-Jan-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 3 1.00 11-Jan-2009 4 1.00 12-Feb-2009
0 0 0 0 0 0 0 0 0 3 1.00 05-Feb-2009 1 1.00 05-Mar-2012
0 0 0 0 0 0 0 0 0 3 1.00 12-Feb-2009 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 2 0.00 20-Nov-2008 1 1.00 20-Mar-2009
0 0 0 0 0 0 0 0 0 3 1.00 01-Oct-2008 #NULL! 0.00 #NULL!
0 0 0 0 0 0 0 0 0 3 1.00 26-Mar-2009 1 1.00 01-Oct-2011
0 0 0 0 0 0 0 0 0 2 0.00 12-Feb-2009 1 1.00 07-Sep-2009
0 0 0 0 0 0 0 0 0 3 1.00 01-Oct-2008 4 1.00 05-Nov-2008
0 0 0 0 0 0 0 0 0 4 1.00 24-Sep-2008 1 1.00 27-May-2009
0 0 0 0 0 0 0 0 0 3 1.00 12-Feb-2009 #NULL! 0.00 #NULL!
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DZ EA EB EC ED EE EF EG EH EI EJ EK EL EM
ResoARTch NewART2 reasnewart2 datchangARt2 Resson AdhV1 AdhV2 AdhV3 AdhV4 AdhV5 AdhV6 AdvNeur AdvSkin Bonemarw
7 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
7 #NULL! #NULL! #NULL! 100 100 100 #NULL! 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 #NULL! 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 95 95 95.00 100.00 0 0 0
5 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
7 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
1 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
2 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 1
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 #NULL! 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
7 #NULL! #NULL! #NULL! 100 100 100 #NULL! 100.00 100.00 0 0 0
7 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
7 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
7 #NULL! #NULL! #NULL! 100 99 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
7 #NULL! #NULL! #NULL! 100 100 80 80 100.00 100.00 0 0 0
3 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 1 0
5 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
7 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
3 2 #NULL! 30-Jan-2012 100 100 100 100 100.00 100.00 0 1 0
0 #NULL! 0 #NULL! 100 100 100 100 100.00 100.00 0 0 0
3 #NULL! 0 #NULL! 100 100 100 100 100.00 100.00 0 1 0
7 6 2 #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
5 #NULL! #NULL! #NULL! 100 100 95 95 95.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
7 6 2 #NULL! 100 100 100 100 100.00 100.00 0 0 0
5 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
3 #NULL! 0 #NULL! 100 100 100 100 100.00 100.00 0 1 0
5 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
0 #NULL! #NULL! #NULL! 100 100 100 100 100.00 100.00 0 0 0
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EN EO EP EQ ER ES ET EU EV EW EX EY EZ FA
GI Lipodystrophy TBonART onATT Metabolic MiscAdv ClinNeur rmcmp rmcmprox lmcmp lmcmprox rpcmp rpcmprox lpcmp
0 1.00 0.00 0.00 0 0 1 20.80 20.00 20.10 16.90 12.90 10.40 12.80
0 1.00 0.00 0.00 0 0 1 15.00 13.00 13.00 12.00 13.00 19.00 10.00
0 0.00 0.00 0.00 0 0 0 15.30 15.10 18.70 18.10 9.10 7.80 9.40
0 1.00 0.00 0.00 0 0 1 11.80 11.50 12.40 9.00 8.20 7.70 8.60
0 0.00 #NULL! #NULL! 0 0 0 18.50 18.00 13.40 12.20 9.90 7.70 6.30
0 0.00 #NULL! #NULL! 0 0 0 10.00 10.00 13.00 11.00 10.00 9.00 9.00
0 0.00 #NULL! #NULL! 0 0 0 13.00 12.00 15.00 13.00 4.00 3.00 5.00
0 0.00 #NULL! #NULL! 0 0 0 19.20 18.00 18.40 16.70 14.10 12.40 10.00
0 0.00 0.00 #NULL! 0 0 0 12.60 10.90 14.00 13.80 7.40 6.10 7.80
0 0.00 0.00 #NULL! 0 0 0 14.10 13.60 16.70 14.20 11.00 10.20 10.40
1 0.00 0.00 #NULL! 1 0 0 19.00 10.50 19.70 10.40 7.40 4.80 6.80
0 0.00 0.00 0.00 0 0 0 13.90 12.60 13.90 12.70 10.20 9.00 12.90
0 0.00 0.00 #NULL! 0 0 0 15.10 12.40 16.60 14.70 8.40 7.00 8.20
0 0.00 0.00 #NULL! 0 0 0 25.40 24.00 25.30 22.30 12.20 10.00 10.90
0 0.00 0.00 #NULL! 0 0 0 18.00 18.00 18.00 16.00 12.00 12.00 12.00
0 0.00 0.00 #NULL! 0 0 0 10.00 10.00 13.00 13.00 6.00 5.00 2.00
0 0.00 0.00 #NULL! 0 0 0 15.00 13.00 10.00 8.00 5.00 5.00 5.00
0 0.00 0.00 #NULL! 0 0 0 15.00 14.00 15.00 14.00 20.00 20.00 15.00
0 0.00 0.00 #NULL! 0 0 0 19.50 19.00 19.20 18.20 7.30 6.60 5.00
0 0.00 0.00 #NULL! 0 0 0 15.00 15.00 18.00 15.00 13.00 13.00 10.00
0 0.00 #NULL! #NULL! 0 0 0 20.80 20.50 28.10 23.30 10.10 9.70 14.10
0 1.00 0.00 0.00 0 0 0 14.50 14.10 12.70 12.10 5.40 4.30 6.30
0 0.00 #NULL! #NULL! 0 0 0 22.00 22.00 20.00 20.00 7.00 7.00 8.00
0 0.00 #NULL! #NULL! 0 0 0 13.00 12.00 20.00 18.00 6.00 6.00 7.00
0 1.00 0.00 0.00 0 0 0 10.00 10.00 13.00 12.00 20.00 17.00 20.00
0 0.00 #NULL! #NULL! 0 0 0 25.00 20.00 18.00 15.00 12.00 10.00 10.00
0 0.00 0.00 0.00 0 0 0 17.00 15.00 15.00 15.00 3.50 3.00 4.00
0 0.00 #NULL! #NULL! 0 0 0 23.00 20.00 25.00 20.00 6.00 6.00 6.00
0 1.00 0.00 0.00 0 0 0 13.00 12.00 12.00 10.00 8.00 8.00 8.00
0 0.00 #NULL! #NULL! 0 0 0 11.70 10.70 17.00 15.60 7.80 5.90 7.20
0 0.00 #NULL! #NULL! 0 0 0 18.00 15.40 22.60 22.20 11.20 10.30 12.30
0 0.00 #NULL! #NULL! 0 0 0 18.00 15.00 21.00 20.00 12.00 8.00 12.00
0 1.00 0.00 0.00 0 0 0 20.00 28.00 18.00 16.00 10.00 8.00 10.00
0 0.00 #NULL! #NULL! 0 0 0 13.00 12.20 15.70 15.80 12.90 12.80 12.10
0 1.00 0.00 0.00 0 0 0 14.30 14.10 14.00 13.90 9.80 8.50 13.10
0 1.00 0.00 0.00 0 hbsag 0 12.60 8.70 11.10 10.10 13.70 13.10 7.00
0 0.00 #NULL! #NULL! 0 0 0 12.40 10.50 14.30 13.30 7.10 5.20 9.00
0 1.00 0.00 0.00 0 0 0 11.30 10.40 12.40 9.70 13.30 11.70 10.20
0 0.00 #NULL! #NULL! 0 0 0 12.00 10.00 10.00 10.00 15.00 12.00 12.00
0 0.00 #NULL! #NULL! 0 0 0 15.00 15.00 18.00 15.00 10.00 8.00 10.00
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FB FC FD FE FF FG FH FI FJ FK FL FM FN FO
lpcmprox rmdl lmdl rpdl lpdl rmf lmf rpf lpf rmcv lmcv rpcv lpcv rmsnp
12.10 3.40 3.10 3.00 3.50 26.10 26.70 45.80 43.40 64.00 63.00 48.00 51.00 21.00
10.00 3.16 3.46 3.72 2.04 26.60 27.80 52.00 51.20 5.80 54.00 46.50 46.20 40.00
8.20 2.80 2.30 3.10 3.40 24.80 26.70 44.40 45.70 58.00 52.00 59.00 50.00 28.00
6.80 2.80 2.80 3.50 3.90 26.00 23.70 42.80 47.90 53.00 58.00 48.00 44.00 29.00
4.40 2.80 2.70 2.40 2.20 24.50 23.20 44.40 42.70 58.00 59.00 53.00 51.00 19.00
8.00 3.44 2.96 3.56 3.78 24.60 25.40 46.20 43.20 56.80 54.80 41.90 42.80 30.00
4.00 3.96 2.92 2.96 2.96 25.80 25.40 43.10 48.00 77.90 61.40 47.00 53.00 20.00
7.80 3.20 3.20 3.20 3.60 29.00 30.50 49.80 48.60 60.00 62.00 49.00 54.00 24.00
7.00 5.20 4.10 3.50 3.50 32.50 28.00 44.80 46.80 54.00 53.00 47.00 47.00 33.00
9.70 3.40 3.00 3.30 3.30 28.30 27.20 46.10 49.90 61.00 51.00 53.00 50.00 40.00
5.10 3.00 2.20 2.70 3.00 26.10 26.10 45.60 49.00 52.00 42.30 42.00 50.00 29.00
11.20 3.50 2.80 3.30 3.20 27.30 27.20 44.20 45.00 63.00 54.00 51.00 56.00 38.00
6.20 3.70 3.20 3.90 4.20 28.30 28.20 49.80 54.70 52.00 42.00 40.00 38.00 25.00
8.60 2.50 2.30 3.00 2.80 24.90 23.90 57.80 46.10 56.00 57.00 49.00 49.00 30.00
10.00 3.04 3.32 3.28 3.44 23.60 24.40 36.60 37.00 59.60 60.60 55.10 58.20 40.00
2.00 3.30 3.00 3.64 3.84 25.20 23.80 49.00 47.40 65.70 65.50 52.40 51.30 20.00
4.00 3.36 3.40 3.32 3.08 26.80 26.40 48.20 48.00 53.00 51.20 49.50 42.70 40.00
14.00 3.26 3.52 3.72 3.12 26.20 23.80 40.80 41.20 65.20 70.60 62.10 66.80 40.00
4.20 3.40 3.00 2.90 2.80 28.90 29.80 45.50 47.70 53.00 59.00 45.00 43.00 38.00
8.00 3.40 2.72 3.16 2.80 24.20 25.20 45.60 45.00 65.10 59.00 58.40 52.40 40.00
11.80 2.90 2.60 2.70 2.60 26.20 24.70 36.00 35.20 66.00 69.00 60.00 53.00 40.00
5.10 3.10 2.90 3.90 3.30 26.40 26.60 49.10 50.60 59.00 60.00 47.00 42.00 27.00
7.00 2.52 2.60 2.96 3.48 25.80 20.80 37.80 40.40 61.10 61.80 53.50 52.90 40.00
7.00 3.04 2.72 3.08 3.68 26.40 25.60 50.80 49.00 63.10 52.30 46.90 50.10 20.00
18.00 3.26 3.16 3.72 3.24 26.20 26.40 41.80 41.20 67.60 55.00 48.40 44.50 40.00
8.00 3.06 2.86 3.12 3.32 25.60 26.00 45.60 42.80 48.70 50.00 49.70 55.70 25.00
4.00 3.20 3.16 3.44 3.72 27.20 24.60 52.00 50.80 49.10 54.20 46.10 54.20 30.00
6.00 3.00 3.08 3.92 3.90 24.80 23.60 42.60 46.00 55.60 59.40 57.50 54.60 60.00
6.00 3.24 3.52 3.28 3.80 22.60 22.20 46.60 40.80 69.20 67.40 56.50 62.90 25.00
6.30 2.90 3.00 3.20 3.10 22.40 25.80 43.60 42.40 56.00 57.00 46.00 49.00 54.00
10.90 3.40 3.00 2.60 3.50 21.50 22.90 43.30 40.60 59.00 58.00 49.00 55.00 41.00
10.00 3.32 3.28 3.96 4.04 26.60 28.60 45.20 49.40 54.30 54.10 48.30 42.70 30.00
10.00 3.48 3.68 3.88 4.12 26.80 27.20 43.80 45.00 53.90 63.80 49.30 46.00 40.00
12.00 3.10 3.30 3.60 3.70 28.10 28.20 54.10 49.70 64.00 60.00 53.00 51.00 57.00
11.30 3.00 3.20 3.30 3.40 25.30 25.70 45.80 44.50 61.00 68.00 49.00 50.00 32.00
6.90 5.80 5.20 3.20 3.80 26.00 27.20 46.20 47.80 59.00 57.00 48.00 51.00 23.00
7.60 3.20 3.00 3.40 3.40 28.00 26.90 47.30 47.20 58.00 60.00 40.00 40.00 34.00
9.00 2.90 2.70 2.90 2.90 22.60 21.70 41.00 42.80 67.00 74.00 54.00 55.00 46.00
10.00 3.72 2.88 3.60 3.32 26.20 25.20 47.40 49.80 51.70 51.00 49.30 56.60 20.00
8.00 3.36 3.08 3.76 3.40 24.80 24.00 46.20 46.20 55.30 65.60 45.90 48.00 40.00
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FP
lmsnp
29.00
30.00
30.00
45.00
23.00
30.00
25.00
22.00
37.00
40.00
24.00
36.00
16.00
42.00
40.00
20.00
40.00
40.00
29.00
40.00
44.00
26.00
40.00
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25.00
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30.00
46.00
67.00
25.00
40.00
47.00
30.00
25.00
34.00
42.00
20.00
40.00
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FQ FR FS FT FU FV FW FX FY FZ GA GB GC GD
rsnp lssnp rucmp rucmprox lucmp lucmprox rudl ludl ruf luf rucv lucv rusnp lusnp
43.00 35.00 15.50 14.60 13.80 13.20 2.90 3.00 25.40 26.60 63.00 69.00 23.00 21.00
30.00 20.00 13.00 13.00 12.00 12.00 2.64 2.68 23.80 28.60 53.10 53.70 20.00 20.00
21.00 21.00 20.50 19.60 17.60 16.50 2.20 1.80 27.70 25.10 64.00 59.00 34.00 33.00
20.00 20.00 14.30 13.80 10.00 9.70 2.40 2.70 25.60 28.20 57.00 52.00 23.00 26.00
32.00 36.00 15.10 14.50 11.50 11.00 2.20 2.30 26.90 25.60 57.00 64.00 40.00 24.00
40.00 40.00 8.00 8.00 9.00 8.00 2.88 2.60 22.80 25.40 57.10 62.50 20.00 20.00
20.00 20.00 14.00 13.00 12.00 11.00 2.80 3.04 25.80 24.60 61.50 64.50 20.00 30.00
23.00 28.00 15.40 13.90 14.30 13.40 2.70 3.00 29.20 30.30 66.00 75.00 48.00 24.00
24.00 30.00 17.90 15.80 18.50 17.50 3.50 3.20 28.20 29.00 54.00 56.00 26.00 21.00
25.00 26.00 17.20 15.20 17.30 16.00 2.40 2.40 29.00 29.20 59.00 65.00 34.00 31.00
21.00 30.00 15.40 11.30 15.20 12.90 2.20 2.10 25.30 24.50 59.00 56.00 23.00 29.00
24.00 20.00 18.40 17.60 17.70 16.90 2.80 2.20 28.70 26.50 55.00 65.00 25.00 30.00
21.00 19.00 14.80 14.70 14.80 11.80 2.50 2.30 27.10 27.60 56.00 60.00 14.00 17.00
17.00 17.00 18.20 16.60 15.40 14.10 1.90 1.70 26.60 26.80 63.00 55.00 22.00 22.00
25.00 25.00 15.00 15.00 15.00 15.00 1.88 2.08 23.60 22.60 63.00 67.60 30.00 25.00
25.00 25.00 13.00 13.00 13.00 12.00 2.64 2.72 24.80 23.60 65.50 67.60 30.00 40.00
20.00 20.00 14.00 12.00 10.00 8.00 2.56 2.92 26.20 26.40 51.20 54.80 20.00 20.00
50.00 50.00 20.00 20.00 20.00 20.00 1.56 1.72 25.40 23.80 58.50 68.00 30.00 40.00
65.00 50.00 17.20 17.00 15.20 12.10 2.60 2.70 25.00 29.30 59.00 57.00 29.00 29.00
20.00 20.00 17.00 16.00 17.00 15.00 2.68 2.72 23.80 24.20 64.70 5.30 20.00 20.00
22.00 29.00 18.50 17.20 18.20 17.10 2.40 2.50 22.80 23.80 68.00 74.00 31.00 22.00
19.00 22.00 14.10 12.50 14.10 12.50 2.10 2.20 28.30 31.40 56.00 54.00 20.00 22.00
50.00 50.00 12.00 12.00 11.00 10.00 1.68 1.76 24.80 23.20 63.60 66.70 25.00 20.00
40.00 40.00 14.00 14.00 15.00 15.00 3.04 3.00 25.40 27.60 69.00 68.00 25.00 25.00
50.00 50.00 15.00 15.00 15.00 15.00 2.88 2.52 26.20 24.60 51.50 56.40 20.00 20.00
30.00 20.00 12.00 10.00 12.00 10.00 2.12 2.27 23.40 24.00 57.70 63.00 25.00 30.00
25.00 25.00 19.00 18.00 17.00 15.00 2.76 2.28 27.00 26.00 57.40 57.70 25.00 25.00
40.00 20.00 20.00 20.00 16.00 15.00 2.96 2.80 24.20 24.00 78.40 63.00 40.00 40.00
20.00 25.00 15.00 15.00 13.00 12.00 2.72 2.76 23.40 22.60 64.10 70.50 20.00 25.00
23.00 41.00 13.70 12.90 16.80 15.50 1.90 2.20 25.90 24.60 69.00 69.00 44.00 49.00
62.00 59.00 15.50 14.80 16.30 15.80 2.50 2.40 21.20 23.50 58.00 57.00 36.00 24.00
40.00 40.00 15.00 15.00 13.00 12.00 2.44 2.04 27.80 25.20 58.50 55.20 20.00 30.00
25.00 30.00 18.00 16.00 15.00 13.00 2.16 2.96 26.20 25.60 57.80 56.20 25.00 25.00
49.00 46.00 17.80 17.40 18.90 17.80 2.40 2.40 30.20 26.50 57.00 58.00 19.00 20.00
34.00 24.00 12.90 11.90 14.70 14.20 2.40 2.60 26.60 26.40 65.00 65.00 26.00 34.00
23.00 21.00 13.70 13.10 16.70 15.70 2.20 2.70 26.60 28.00 60.00 63.00 38.00 23.00
25.00 21.00 8.10 6.70 8.40 7.90 2.10 2.60 28.20 27.00 58.00 65.00 26.00 23.00
94.00 62.00 15.60 14.70 18.60 16.30 2.20 2.10 22.10 22.60 67.00 67.00 40.00 33.00
30.00 25.00 12.00 12.00 10.00 10.00 2.68 2.92 26.20 26.00 50.40 57.10 20.00 20.00
40.00 50.00 15.00 15.00 12.00 10.00 1.92 2.36 26.20 24.00 50.40 63.00 40.00 30.00
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GF GG GH GI GJ GK GL GM GN GO GP GQ GR GS
CD4d bmi20 rmcmpF6 rmcppF6 lmcpF6 lmcppF6 rpcpF6 rpcppF6 lpcpF6 lpcppF6 rmdlF6 lmdlF6 rpdlF6 lpdlF6
3.00 1.00 11.50 11.10 12.20 11.60 12.20 10.60 12.00 10.10 4.10 4.10 3.40 3.60
4.00 0.00 16.60 15.20 14.70 14.20 9.20 7.20 7.30 6.10 3.00 3.10 3.60 3.60
3.00 0.00 17.80 15.20 18.40 18.60 13.90 12.00 12.00 11.10 3.10 3.00 3.60 3.80
3.00 1.00 18.20 17.40 16.90 16.00 8.30 7.40 6.10 5.50 2.80 3.00 3.40 3.40
3.00 1.00 10.50 9.40 11.10 9.20 8.30 6.80 5.10 4.40 4.80 5.00 4.20 4.30
1.00 1.00 11.30 10.20 13.00 11.00 7.80 6.50 11.30 9.70 2.70 2.50 2.60 3.00
3.00 1.00 11.40 11.20 14.80 13.40 2.60 1.80 5.40 4.50 2.90 2.50 2.90 2.80
3.00 0.00 14.40 13.20 16.90 13.60 12.20 11.30 10.50 9.30 3.80 3.50 3.40 3.80
4.00 0.00 14.20 11.80 9.50 9.30 7.50 6.50 10.70 8.60 3.20 3.10 3.90 4.00
1.00 0.00 19.90 18.80 18.30 18.80 12.90 11.00 13.30 11.30 3.10 3.10 3.30 3.20
4.00 0.00 11.10 10.40 11.80 11.50 10.20 7.10 7.70 6.10 3.20 2.80 2.90 2.80
3.00 0.00 14.20 11.80 9.50 9.30 7.50 6.50 10.70 8.60 3.20 3.10 3.90 4.00
2.00 1.00 13.20 11.10 16.60 13.40 17.10 12.40 9.80 7.70 2.90 3.00 3.00 3.30
4.00 0.00 22.90 20.80 20.50 20.50 4.80 3.70 13.70 10.30 2.80 2.60 2.70 3.00
4.00 0.00 17.80 16.20 26.50 21.10 12.50 11.40 8.30 6.50 3.20 2.50 3.40 3.90
2.00 1.00 13.20 11.10 16.60 13.40 17.10 12.40 9.80 7.70 2.90 3.00 3.00 3.30
3.00 0.00 17.00 16.10 14.60 12.90 7.30 6.40 7.10 6.30 3.10 3.10 3.20 3.40
4.00 1.00 16.60 13.80 14.80 11.80 10.00 9.40 10.40 9.00 3.30 2.80 2.90 2.90
4.00 0.00 13.20 11.10 16.60 13.40 17.10 12.40 9.80 7.70 2.90 3.00 3.00 3.30
2.00 0.00 13.40 10.00 22.10 21.00 9.00 8.50 7.20 6.70 2.80 2.50 2.80 2.40
4.00 1.00 26.30 24.80 21.00 20.50 9.20 8.50 11.90 11.10 3.20 3.10 3.00 3.10
3.00 0.00 14.60 14.20 14.00 12.50 9.30 7.70 7.30 4.70 3.40 2.90 3.80 3.80
3.00 0.00 23.90 23.40 23.80 23.40 11.30 9.30 10.70 8.80 2.30 2.50 2.90 2.90
3.00 0.00 13.00 12.10 15.00 14.50 8.40 6.20 7.30 6.00 2.80 2.60 2.50 3.10
1.00 0.00 11.60 10.60 16.20 15.50 18.40 16.30 21.60 18.20 2.70 2.50 2.90 2.90
3.00 0.00 14.20 11.80 9.50 9.30 7.50 6.50 10.70 8.60 3.20 3.10 3.90 4.00
3.00 1.00 13.20 12.30 17.30 16.40 6.30 4.00 3.80 2.30 2.70 2.60 2.90 3.10
4.00 1.00 19.10 18.80 15.30 14.40 6.70 6.50 5.10 4.20 3.10 2.90 3.80 3.70
4.00 1.00 7.80 7.70 11.40 11.00 8.40 7.10 9.00 7.50 2.90 2.90 3.60 3.30
3.00 0.00 16.80 15.60 18.10 17.50 10.00 7.90 9.80 8.30 2.90 3.50 3.90 3.40
4.00 1.00 11.10 10.40 11.80 11.50 10.20 7.10 7.70 6.10 3.20 2.80 2.90 2.80
4.00 1.00 16.50 15.90 22.90 20.20 13.50 10.80 10.10 8.90 3.00 3.20 3.70 3.90
4.00 1.00 10.50 9.40 11.10 9.20 8.30 6.80 5.10 4.40 4.80 5.00 4.20 4.30
4.00 0.00 10.50 9.40 11.10 9.20 8.30 6.80 5.10 4.40 4.80 5.00 4.20 4.30
2.00 1.00 16.30 16.10 19.10 18.30 13.60 12.60 13.10 13.00 3.30 3.30 3.80 3.90
2.00 1.00 13.70 13.00 13.80 14.50 7.40 7.50 7.20 6.70 3.10 3.20 4.00 4.30
2.00 0.00 12.20 11.70 15.00 14.70 7.60 5.70 10.40 8.40 3.20 3.00 3.20 3.60
3.00 1.00 12.10 11.20 12.80 12.40 12.20 10.60 10.10 8.80 2.70 2.80 2.60 2.80
3.00 0.00 11.10 10.40 11.80 11.50 10.20 7.10 7.70 6.10 3.20 2.80 2.90 2.80
2.00 1.00 20.70 20.20 24.50 23.60 9.10 7.40 9.10 7.30 2.60 2.50 3.60 2.80
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rmfF6
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24.50
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26.30
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GU GV GW GX GY GZ HA HB HC HD HE HF HG HH
lmfF6 rpfF6 lpfF6 rmcvF6 lmcvF6 rpcvF6 lpcvF6 rmsnpF6 lmsnpF6 rssnpF6 lssnpF6 rucpF6 rucppF6 lucpF6
26.80 42.80 44.90 64.00 58.00 50.00 51.00 48.00 29.00 20.00 18.00 17.10 16.00 15.40
28.80 52.50 52.30 50.00 50.00 42.00 42.00 22.00 22.00 6.00 9.00 13.50 11.60 11.80
26.20 47.70 45.90 57.00 53.00 51.00 49.00 25.00 20.00 23.00 20.00 23.50 21.80 23.60
25.40 47.90 49.90 61.00 67.00 45.00 47.00 35.00 36.00 12.00 0.00 20.20 18.90 14.90
28.10 56.10 54.10 58.00 55.00 38.00 39.00 23.00 28.00 11.00 3.00 14.40 11.40 11.90
24.50 46.50 43.80 57.00 60.00 46.00 54.00 25.00 27.00 28.00 25.00 13.10 10.00 10.80
25.00 48.70 47.50 57.00 55.00 50.00 54.00 35.00 36.00 0.00 12.00 13.30 12.00 14.20
29.50 49.50 49.10 57.00 55.00 46.00 47.00 25.00 31.00 16.00 4.00 14.90 13.00 13.00
24.50 45.60 48.10 61.00 68.00 43.00 52.00 36.00 77.00 23.00 31.00 #NULL! #NULL! #NULL!
32.60 46.60 47.60 58.00 58.00 52.00 52.00 24.00 25.00 20.00 25.00 19.20 15.20 21.30
22.30 43.00 44.10 61.00 61.00 51.00 49.00 50.00 52.00 23.00 27.00 19.20 17.20 22.20
24.50 45.60 48.10 61.00 68.00 43.00 52.00 36.00 77.00 23.00 31.00 16.80 13.10 14.70
25.20 42.30 41.00 60.00 76.00 54.00 54.00 24.00 21.00 17.00 17.00 19.80 16.80 16.10
24.90 44.80 48.50 58.00 63.00 52.00 52.00 34.00 56.00 16.00 23.00 16.00 14.20 13.80
24.20 42.30 44.90 66.00 58.00 53.00 57.00 22.00 50.00 21.00 20.00 21.30 20.20 18.90
25.20 42.30 41.00 60.00 76.00 54.00 54.00 24.00 21.00 17.00 17.00 #NULL! #NULL! #NULL!
27.30 50.50 50.30 55.00 55.00 44.00 45.00 45.00 41.00 22.00 21.00 15.30 15.20 14.70
22.90 41.20 46.40 62.00 61.00 55.00 56.00 102.00 100.00 43.00 37.00 19.40 18.40 19.50
25.20 42.30 41.00 60.00 76.00 54.00 54.00 24.00 21.00 17.00 17.00 19.80 16.80 16.10
28.00 46.20 43.20 58.00 69.00 53.00 53.00 21.00 25.00 21.00 23.00 15.90 15.50 12.40
23.00 37.40 39.60 60.00 71.00 54.00 61.00 31.00 21.00 44.00 24.00 24.60 22.10 20.00
28.00 51.50 50.40 60.00 59.00 48.00 51.00 21.00 23.00 15.00 21.00 21.20 19.20 14.40
22.50 38.40 43.70 62.00 66.00 56.00 54.00 54.00 47.00 31.00 21.00 19.00 18.70 15.60
25.90 48.70 48.40 58.00 53.00 49.00 50.00 35.00 29.00 49.00 52.00 13.50 12.70 14.60
24.50 43.70 46.10 59.00 62.00 52.00 54.00 25.00 20.00 20.00 28.00 15.20 14.20 17.70
24.50 45.60 48.10 61.00 68.00 43.00 52.00 36.00 77.00 23.00 31.00 16.80 13.10 14.70
28.00 45.30 48.80 57.00 51.00 44.00 43.00 31.00 29.00 29.00 27.00 16.30 13.60 15.00
28.30 46.70 43.90 63.00 69.00 51.00 50.00 72.00 44.00 33.00 33.00 17.70 14.80 17.50
22.60 40.10 42.80 58.00 66.00 55.00 56.00 45.00 49.00 28.00 22.00 13.80 12.40 11.00
26.80 47.10 44.20 55.00 57.00 52.00 57.00 29.00 31.00 30.00 22.00 17.10 15.20 20.20
22.30 43.00 44.10 61.00 61.00 51.00 49.00 50.00 52.00 23.00 27.00 #NULL! #NULL! #NULL!
25.70 50.40 54.00 58.00 60.00 51.00 52.00 46.00 36.00 36.00 26.00 16.20 14.10 17.10
28.10 56.10 54.10 58.00 55.00 38.00 39.00 23.00 28.00 11.00 3.00 #NULL! #NULL! #NULL!
28.10 56.10 54.10 58.00 55.00 38.00 39.00 23.00 28.00 11.00 3.00 14.40 11.40 11.90
25.40 45.10 43.40 61.00 65.00 53.00 58.00 62.00 46.00 37.00 37.00 16.10 16.00 17.10
27.60 48.00 49.20 68.00 62.00 54.00 55.00 31.00 29.00 29.00 26.00 18.80 17.90 13.80
26.30 48.10 45.50 57.00 60.00 51.00 52.00 32.00 24.00 27.00 20.00 8.50 7.40 9.20
22.60 39.60 40.10 69.00 69.00 56.00 55.00 39.00 47.00 38.00 63.00 14.60 14.20 14.60
22.30 43.00 44.10 61.00 61.00 51.00 49.00 50.00 52.00 23.00 27.00 19.20 17.20 22.20
23.00 43.50 44.10 57.00 66.00 51.00 51.00 83.00 43.00 21.00 22.00 20.20 18.60 17.60
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HI
lucppF6
12.00
9.70
22.20
11.00
10.70
10.80
12.90
12.40
#NULL!
19.20
21.70
14.20
15.20
11.70
18.90
#NULL!
12.50
18.90
15.20
10.90
18.90
12.90
12.70
13.20
15.40
14.20
12.90
13.20
10.90
17.70
#NULL!
14.10
#NULL!
10.70
15.80
13.00
8.60
13.10
21.70
16.10
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HJ HK HL HM HN HO HP HQ HR HS HT HU HV HW
rudlF6 ludlF6 rufF6 lufF6 rucvF6 lucvF6 rusnpF6 lusnpF6 duroart1 VAR00012 DuraART duradiseae crntdate duradiseaeinwks
2.80 2.50 28.50 28.00 64.00 60.00 26.00 20.00 1,015.00 1,015.00 3.00 -1,492.00 15-Mar-2013 -213.14
2.50 8.40 30.70 30.40 46.00 54.00 5.00 9.00 1,289.00 1,289.00 3.00 -1,541.00 15-Mar-2013 -220.14
2.50 2.50 26.70 26.60 60.00 75.00 44.00 33.00 #NULL! 1,443.00 3.00 -1,443.00 15-Mar-2013 -206.14
2.10 2.10 27.20 26.50 58.00 62.00 20.00 22.00 #NULL! 1,576.00 3.00 -1,576.00 15-Mar-2013 -225.14
2.90 3.40 29.10 30.70 48.00 51.00 19.00 #NULL! 97.00 97.00 1.00 -1,612.00 15-Mar-2013 -230.29
1.90 2.20 27.80 25.10 63.00 72.00 31.00 30.00 1,298.00 1,298.00 3.00 -1,562.00 15-Mar-2013 -223.14
2.80 2.50 27.40 27.20 60.00 70.00 67.00 61.00 #NULL! 1,576.00 3.00 -1,576.00 15-Mar-2013 -225.14
3.40 3.20 29.10 29.30 57.00 62.00 25.00 20.00 #NULL! 1,457.00 3.00 -1,457.00 15-Mar-2013 -208.14
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! 1,576.00 3.00 -1,576.00 15-Mar-2013 -225.14
2.40 2.30 27.30 28.50 59.00 59.00 24.00 26.00 #NULL! 1,387.00 3.00 -1,387.00 15-Mar-2013 -198.14
2.00 1.70 22.90 23.90 66.00 63.00 33.00 #NULL! 105.00 105.00 1.00 -1,633.00 15-Mar-2013 -233.29
2.40 2.60 24.20 25.10 67.00 70.00 23.00 16.80 #NULL! 1,612.00 3.00 -1,612.00 15-Mar-2013 -230.29
2.50 2.80 26.00 26.10 67.00 77.00 20.00 #NULL! 34.00 34.00 1.00 -1,513.00 15-Mar-2013 -216.14
2.60 2.10 26.30 26.80 68.00 64.00 38.00 28.00 #NULL! 1,408.00 3.00 -1,408.00 15-Mar-2013 -201.14
2.20 2.10 24.30 23.70 74.00 71.00 23.00 27.00 #NULL! 1,408.00 3.00 -1,408.00 15-Mar-2013 -201.14
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! 1,597.00 3.00 -1,597.00 15-Mar-2013 -228.14
2.60 2.50 27.60 24.90 66.00 57.00 27.00 20.00 #NULL! 1,541.00 3.00 -1,541.00 15-Mar-2013 -220.14
2.40 1.80 30.80 24.00 61.00 63.00 35.00 42.00 #NULL! 1,506.00 3.00 -1,506.00 15-Mar-2013 -215.14
2.50 2.80 26.00 26.10 67.00 77.00 20.00 19.80 1,407.00 1,407.00 3.00 -1,668.00 15-Mar-2013 -238.29
2.20 2.30 24.60 23.20 70.00 67.00 22.00 27.00 1,097.00 1,097.00 3.00 -1,422.00 15-Mar-2013 -203.14
2.00 2.30 22.50 23.90 61.00 61.00 22.00 24.00 1,114.00 1,114.00 3.00 -1,492.00 15-Mar-2013 -213.14
2.40 2.60 26.50 26.60 69.00 57.00 18.00 15.00 37,124.00 37,124.00 3.00 -1,582.00 15-Mar-2013 -226.00
1.60 2.10 21.90 22.60 68.00 71.00 26.00 34.00 #NULL! 1,499.00 3.00 -1,499.00 15-Mar-2013 -214.14
2.50 2.40 28.30 27.50 59.00 64.00 26.00 25.00 #NULL! 1,464.00 3.00 -1,464.00 15-Mar-2013 -209.14
2.10 2.20 25.20 25.20 61.00 63.00 22.00 21.00 1,077.00 1,077.00 3.00 -1,506.00 15-Mar-2013 -215.14
2.40 2.60 24.20 25.10 67.00 70.00 23.00 #NULL! 15.00 15.00 1.00 -1,373.00 15-Mar-2013 -196.14
2.50 2.40 28.50 26.30 58.00 65.00 24.00 24.00 274.00 274.00 2.00 -1,780.00 15-Mar-2013 -254.29
2.30 2.30 27.30 24.70 66.00 65.00 33.00 27.00 923.00 923.00 3.00 -1,541.00 15-Mar-2013 -220.14
2.60 2.30 24.20 23.60 70.00 62.00 39.00 34.00 323.00 323.00 2.00 -1,191.00 15-Mar-2013 -170.14
2.30 2.50 24.60 25.10 64.00 73.00 21.00 29.00 #NULL! 1,528.00 3.00 -1,528.00 15-Mar-2013 -218.29
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! 32.00 32.00 1.00 -1,524.00 15-Mar-2013 -217.71
2.50 2.50 27.90 25.30 68.00 66.00 23.00 25.00 1,124.00 1,124.00 3.00 -1,499.00 15-Mar-2013 -214.14
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! 1,492.00 3.00 -1,492.00 15-Mar-2013 -213.14
2.90 3.40 29.10 30.70 48.00 51.00 19.00 14.40 120.00 120.00 1.00 -1,576.00 15-Mar-2013 -225.14
2.60 2.90 26.40 25.20 69.00 65.00 24.00 18.00 #NULL! 1,625.00 3.00 -1,626.00 15-Mar-2013 -232.29
3.20 2.70 28.10 25.30 63.00 56.00 24.00 22.00 919.00 919.00 3.00 -1,450.00 15-Mar-2013 -207.14
2.40 2.30 26.50 29.50 67.00 65.00 35.00 19.00 207.00 207.00 2.00 -1,492.00 15-Mar-2013 -213.14
1.90 2.00 23.20 23.30 69.00 59.00 35.00 51.00 35.00 35.00 1.00 -1,626.00 15-Mar-2013 -232.29
2.00 1.70 22.90 23.90 66.00 63.00 33.00 19.20 245.00 245.00 2.00 -1,633.00 15-Mar-2013 -233.29
2.10 2.10 24.90 23.70 68.00 67.00 20.00 56.00 #NULL! 1,492.00 3.00 -1,492.00 15-Mar-2013 -213.14
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HX HY HZ IA IB IC ID IE IF IG IH II
duradiseaeinmonths wtincreas wtdecreas wtdecreasonly cd4noincrease lastcd4less200 catchangeinARTtime TNSsensory TNSmotor TNSautonomuic TNSpinsen TNSvibration
-49.73 1.00 0.00 0.00 0.00 0.00 2.00 3.00 0.00 0.00 2.00 2.00
-51.37 1.00 0.00 0.00 0.00 0.00 2.00 1.00 0.00 0.00 1.00 1.00
-48.10 1.00 0.00 0.00 0.00 0.00 3.00 1.00 0.00 0.00 1.00 1.00
-52.53 1.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-53.73 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
-52.07 1.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00
-52.53 0.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-48.57 1.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-52.53 0.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-46.23 0.00 1.00 1.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-54.43 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
-53.73 0.00 1.00 1.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-50.43 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
-46.93 1.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-46.93 0.00 1.00 1.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-53.23 0.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-51.37 1.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-50.20 0.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-55.60 1.00 0.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-47.40 1.00 0.00 0.00 0.00 1.00 2.00 0.00 0.00 0.00 0.00 0.00
-49.73 1.00 0.00 0.00 1.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-52.73 1.00 0.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-49.97 0.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-48.80 1.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-50.20 1.00 0.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-45.77 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
-59.33 0.00 1.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-51.37 1.00 0.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-39.70 1.00 0.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-50.93 1.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-50.80 1.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
-49.97 1.00 0.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-49.73 0.00 1.00 1.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-52.53 1.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
-54.20 1.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
-48.33 1.00 0.00 0.00 0.00 1.00 2.00 0.00 0.00 0.00 0.00 0.00
-49.73 0.00 1.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-54.20 0.00 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
-54.43 0.00 0.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00
-49.73 1.00 0.00 0.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00
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IJ IK IL IM IN IO
TNSstrength TNSreflexes TNSQST TNSsural TNSperoneal TNS
0.00 2.00 #NULL! 4.00 4.00 17.00
0.00 1.00 #NULL! 5.00 4.00 13.00
0.00 1.00 #NULL! 5.00 5.00 14.00
0.00 1.00 #NULL! 2.00 3.00 6.00
0.00 0.00 #NULL! 3.00 3.00 6.00
0.00 1.00 #NULL! 2.00 3.00 6.00
0.00 0.00 #NULL! 2.00 2.00 4.00
0.00 1.00 #NULL! 2.00 3.00 6.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
0.00 0.00 #NULL! 0.00 0.00 0.00
